Filed pursuant to Rule 424(b)(5)
Registration No. 333-239441
PROSPECTUS SUPPLEMENT
(to Prospectus dated July 10, 2020)
eMagin Corporation
$10,000,000
COMMON STOCK
We have entered into a sales agreement with H.C. Wainwright & Co.,
LLC, or Wainwright, dated as of November 18, 2021 (the “sales agreement”) relating to shares of our common stock that we may
offer and sell from time to time through Wainwright acting as our sales agent. In accordance with the terms of the sales agreement, we
may offer and sell shares of our common stock pursuant to this prospectus having an aggregate offering price of up to $10,000,000 from
time to time through Wainwright acting as our sales agent.
Our common stock is listed on the NYSE American under the symbol “EMAN.”
On November 17, 2021, the closing sale price of our common stock on the NYSE American was $2.34 per share.
Sales of our common stock, if any, under this prospectus supplement
and the accompanying prospectus may be made in sales deemed to be “at the market” equity offerings as defined in Rule 415
promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the NYSE American, the existing
trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to the sales
agent as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing
market prices, and/or in any other method permitted by law. If we and Wainwright agree on any method of distribution other than sales
of shares of our common stock into the NYSE American or another existing trading market in the United States at market prices, we will
file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act.
Wainwright will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices.
There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
Wainwright will be entitled to compensation at a fixed commission rate
equal to 3.0% of the gross proceeds per share sold under the sales agreement. In connection with the sale of the common stock on our behalf,
Wainwright will be deemed to be an “underwriter” within the meaning of the Securities Act of 1933, as amended, and the compensation
of Wainwright will be deemed to be underwriting commissions or discounts.
Investing in our securities involves significant risks. Please read
the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-3 of this prospectus
supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus
supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
Prospectus Supplement dated November 18, 2021.
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
You should rely only on the information contained or incorporated
by reference in this prospectus supplement, the accompanying prospectus and any free writing prospectuses we may provide to you in connection
with this offering. We have not, and Wainwright has not, authorized any other person to provide you with any information that is different.
If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus supplement, the
accompanying prospectus, the documents incorporated by reference herein and any free writing prospectuses we may provide to you in connection
with this offering is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects
may have changed since those dates. You should not consider this prospectus supplement or the accompanying prospectus to be an offer or
solicitation relating to the securities in any jurisdiction in which such an offer or solicitation relating to the securities is not authorized.
Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any
restrictions relating to, the offering of the securities and the distribution of this prospectus supplement outside the United States.
Furthermore, you should not consider this prospectus supplement or the accompanying prospectus to be an offer or solicitation relating
to the securities if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such
an offer or solicitation.
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is part of the registration statement that we filed with
the Securities and Exchange Commission, or the SEC, using a “shelf” registration process and consists of two parts. The first
part is this prospectus supplement, which describes the specific terms of this offering. The second part, the accompanying prospectus,
gives more general information, some of which may not apply to this offering. Generally, when we refer only to the “prospectus,”
we are referring to both parts combined. This prospectus supplement may add to, update or change information in the accompanying prospectus
and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus. By using a shelf registration
statement, we may offer shares of our common stock having an aggregate offering price of up to $10,000,000 from time to time under this
prospectus supplement at prices and on terms to be determined by market conditions at the time of offering.
If information in this prospectus supplement is inconsistent with the
accompanying prospectus or with any document incorporated by reference that was filed with the SEC before the date of this prospectus
supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying prospectus and the documents incorporated
into each by reference include important information about us, the securities being offered and other information you should know before
investing in our securities. You should also read and consider information in the documents we have referred you to in the sections of
this prospectus supplement entitled “Where You Can Find Additional Information” and “Incorporation of Certain Information
by Reference.”
You should rely only on this prospectus supplement, the accompanying
prospectus, the documents incorporated or deemed to be incorporated by reference herein or therein and any free writing prospectus prepared
by us or on our behalf. We have not, and the underwriters have not, authorized anyone to provide you with information that is in addition
to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. If anyone
provides you with different or inconsistent information, you should not rely on it. We and the underwriters are not offering to sell these
securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this
prospectus supplement, the accompanying prospectus or any free writing prospectus, or incorporated by reference herein, is accurate as
of any date other than as of the date of this prospectus supplement or the accompanying prospectus or any free writing prospectus, as
the case may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery
of this prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition, liquidity,
results of operations and prospects may have changed since those dates.
We further note that the representations, warranties and covenants
made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus supplement
or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you.
Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.
All references in this prospectus supplement or the accompanying prospectus
to “eMagin Corporation,” “eMagin,” “the Company,” “we,” “us,” and “our
Company” refer to eMagin Corporation and its wholly owned subsidiary, Virtual Vision, Inc., unless we state otherwise or the context
otherwise requires.
eMagin® is a registered trademark of eMagin Corporation. dPdTM
is an unregistered trademark of eMagin. All rights reserved. All other trademarks used in this prospectus supplement or the accompanying
prospectus are the property of their respective owners.
No action is being taken in any jurisdiction outside the United
States to permit a public offering of the securities or possession or distribution of this prospectus supplement or the accompanying prospectus
in that jurisdiction. Persons who come into possession of this prospectus supplement or the accompanying prospectus in jurisdictions outside
the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of
this prospectus supplement or the accompanying prospectus applicable to that jurisdiction.
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights selected information contained elsewhere
or incorporated by reference in this prospectus supplement and the accompanying prospectus. This summary does not contain all the information
that you should consider before investing in our securities. You should read the entire prospectus supplement and the accompanying prospectus
carefully, including “Risk Factors” contained in this prospectus supplement, the accompanying prospectus and the documents
incorporated by reference herein and therein and the financial statements incorporated by reference in this prospectus supplement and
the accompanying prospectus, before making an investment decision.
eMagin Corporation
We design, develop, manufacture and market organic light emitting diode,
or OLED miniature displays, which we refer to as OLED-on-silicon microdisplays, virtual imaging products that utilize OLED microdisplays,
and related products. We also perform research in the OLED field. Our virtual imaging products integrate OLED technology with silicon
chips to produce high-resolution microdisplays which, when viewed through a magnifying headset, create virtual images that appear comparable
in size to that of a computer monitor or a large-screen television. Our products enable our original equipment manufacturer, or OEM, customers
in the military and commercial markets to develop and market improved or new electronic products.
We believe that our OLED microdisplays offer a number of significant
advantages over comparable liquid crystal microdisplays, including higher contrast, greater power efficiency, less weight, more compact
size, and negligible image smearing. Using our active matrix OLED technology, many computer and electronic system functions can be built
directly into the OLED microdisplay silicon backplane, resulting in compact, high resolution and power efficient systems. Already proven
in military and commercial systems, our product portfolio of OLED microdisplays deliver high-resolution, virtual images that perform effectively
even in extreme temperatures and high-vibration conditions.
Our OEM customers incorporate our OLED displays in a variety of products
including, military aviation helmets, military weapons sights and targeting systems, night vision and thermal imaging devices, training
and simulation, visualization for ocular surgery, mobile ultrasound, and augmented reality applications.
We believe our technology, intellectual property portfolio and position
in the marketplace give us a leadership position in OLED and OLED-on-silicon microdisplay technology. We have an intellectual property
portfolio that includes 41 U.S. patents and 16 pending U.S. patents, and have over 24 years of manufacturing know-how and other proprietary
technologies to create our high-performance OLED microdisplays. We also have 5 issued foreign patents and 24 foreign filings. We believe
that we are one of only a few companies to market and produce significant quantities of high resolution, small molecule OLED-on-silicon
microdisplays.
We also believe that our direct patterning, or dPd technology, which
we introduced during 2018, gives us an advantage over other OLED microdisplays because it allows us to produce microdisplays with the
high brightness required for VR and AR and certain military applications. Traditional OLED microdisplays utilize white emitting OLED with
color filters that lessen the intensity of emitted light by as much as 80%, significantly reducing brightness. Microdisplays manufactured
by dPd process technology do not require color filters to achieve color variations and allow for the application of more efficient OLED
structures which achieve higher brightness. dPd also allows for much lower power and longer life when run at the same luminance of a color
filter display.
We believe that our U.S.-based design and manufacturing, combined with
in-house advanced backplane design, and our dPd technology give us a competitive advantage. Our direct patterning equipment is operational.
We have fabricated full color displays using the newly upgraded and installed dPd tool during 2021 including our 4kX4k and WUXGA displays.
In July 2021, using our dPd technology we created full color WUXGA displays with a brightness of over 10,000 cd/m2. We continue our development
work for our Tier One Consumer customer and are targeting similar levels of brightness on proof-of-concept displays using our full color
dPd process.
We achieved the highest monochrome brightness levels in the market
years ago and are continuing our leadership with color displays. Display brightness is critical for AR/VR devices because of optics inefficiency
and the need to eliminate motion artifacts. This is especially important for heads up displays used in bright, daylight environments.
Our high resolution and low pixel pitch are also important to eliminate the “screen door” effect that comes with expanding
lower resolution displays over wide fields of view.
We received a validation of our products and technology during 2020
from the U.S. government. In 2020, we received two U.S. Department of Defense, or DoD, awards totaling $39.1 million. We believe
we are the only commercial U.S. manufacturer of OLED microdisplays and our displays are used in many U.S. military programs.
We derive the majority of our revenue from sales of our OLED microdisplay
products. We also earn revenue from commercial, consumer product and government development contracts that may complement and support
our internal research and development programs. In addition, we generate sales from optics and microdisplays combined with optics. And
finally, as the technology leader in this space, we may see future opportunities to license technologies like dPd to OEMs and other global
manufacturers.
We were formed in March 2000 through the merger of Fashion Dynamics
Corporation and FED Corporation, a developer and manufacturer of optical systems and microdisplays for use in the electronics industry.
Simultaneous with this merger, we changed our name to eMagin Corporation. We are incorporated in the state of Delaware.
The address of our principal executive offices is 700 South Drive,
Suite 201, Hopewell Junction, NY 12533 and our telephone number is (845) 838-7900.
The Offering
Issuer
|
|
eMagin Corporation
|
|
|
|
Common stock offered by us
|
|
Shares of our common stock having an aggregate offering price of up to $10,000,000.
|
|
|
|
Common stock to be outstanding after the offering
|
|
Up to 76,835,631 shares, after giving effect to the assumed sale of 4,300,000 shares of our common stock at a price of $2.34 per share, which was the closing price of our common stock on the NYSE American on November 17, 2021. The actual number of shares issued will vary depending on the price at which shares may be sold from time to time during this offering.
|
|
|
|
Manner of offering
|
|
“At the market offering” that may be made from time to time through our sales agent, H.C. Wainwright & Co., LLC. See “Plan of Distribution” on page S-12.
|
|
|
|
Use of proceeds
|
|
We intend to use the net proceeds from this offering to fund working capital requirements and for other general corporate purposes. See “Use of Proceeds” on page S-10.
|
|
|
|
NYSE American symbol
|
|
“EMAN”
|
|
|
|
Risk Factors
|
|
This investment involves a high degree of risk. See the information contained in or incorporated by reference under “Risk Factors” beginning on page S-3 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement.
|
The number of shares of common stock shown above to be outstanding
after this offering is based on 72,535,631 shares outstanding as of September 30, 2021 and excludes:
|
●
|
3,847,757 shares of our common stock issuable upon the exercise of stock options outstanding as of September 30, 2021, at a weighted
average exercise price of $1.92 per share;
|
|
●
|
402,099 shares of our common stock underlying Restricted Stock Units, or RSU’s that are issuable subject to the satisfaction
of certain time-based service criteria;
|
|
●
|
103,048 shares of our common stock underlying RSU’s that are issuable subject to the achievement of certain financial targets
over a performance period, and the satisfaction of certain time based service criteria;
|
|
●
|
18,726,009 shares of common stock issuable upon conversion of our outstanding Series B Convertible Preferred Stock; and
|
|
●
|
3,000,000 shares of our common stock issuable upon the exercise of warrants issued in April 2019 and outstanding as of September 30,
2021, at an exercise price of $0.78 per share; 1,680,447 shares of our common stock issuable upon the exercise of warrants issued in August
2016 and outstanding as of September 30, 2021, at an exercise price of $2.60 per share; 100,000 shares of our common stock issuable upon
the exercise of warrants issued in March 2017 and outstanding as of September 30, 2021, at an exercise price of $2.25 per share, 1,650,000
shares of our common stock issuable upon the exercise of warrants issued in May 2017 and outstanding as of September 30, 2021, at an exercise
price of $2.45 per share; and 2,909,369 shares of our common stock issuable upon the exercise of warrants issued in January 2018 and outstanding
as of September 30, 2021, at an exercise price of $1.55 per share.
|
Unless otherwise stated, all information contained in this prospectus
supplement reflects an assumed public offering price of $2.34 per share, which was the closing sales price of our common stock on the
NYSE American on November 17, 2021.
RISK
FACTORS
Investing
in our securities involves a high degree of risk. In addition to the other information contained in this prospectus supplement to the
accompanying prospectus and in the documents we incorporate by reference, you should carefully consider the risks discussed below and
under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and our Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 2021 before making a decision about investing in our securities. The
risks and uncertainties discussed below and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and our Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 2021 are not the only ones facing us. Additional risks and uncertainties
not presently known to us may also harm our business. If any of these risks occur, our business, financial condition and operating results
could be harmed, the trading price of our common stock could decline and you could lose part or all of your investment.
Risks
Related to this Offering and Our Common Stock
The
market price of our common stock may be volatile.
The
market price of our common stock has been subject to wide fluctuations. During our four most recently completed fiscal quarters, the
closing price of our stock ranged from a low of $1.06 to a high of $4.84. The market price of our common stock in the future is likely
to continue to be subject to wide fluctuations in response to various factors, including, but not limited to, the following:
|
●
|
variations
in our operating results and financial conditions;
|
|
●
|
sales
by our existing shareholders;
|
|
●
|
changes
in financial estimates or investment recommendations by securities analysts following our
business;
|
|
●
|
actual
or anticipated announcements of technical innovations, commercial partnerships, new product
developments, or design wins by us or our competitors;
|
|
●
|
general
conditions in the semiconductor and display industries; and
|
|
●
|
worldwide
economic and financial conditions.
|
In
addition, the public stock markets have experienced extreme price and volume fluctuations that have particularly affected the market
price for many technology companies and that have often been unrelated to the operating performance of these companies. The broad market
fluctuations and other factors may continue to adversely affect the market price of our common stock.
Provisions
in certain of our commercial agreements and our military business may prevent or delay an acquisition of, partnership with, or investment
in us, and our ability to develop OEM and mass production partnerships, which could decrease the market value of our common stock.
Provisions
in certain of our commercial agreements may discourage, delay or prevent a merger, acquisition or other change in control that stockholders
may consider favorable. In addition, as a contractor and subcontractor to the U.S. federal government, we are subject to and must comply
with various government regulations that impact our operating costs, profit margins and the internal organization and operation of our
business. As a result, these provisions and business may prevent or delay an acquisition of, partnership with, or investment in, our
Company and our ability to develop OEM and mass production partnerships and could limit the price that strategic investors may be willing
to pay in the future for shares of our common stock. They could also deter potential partners or acquirers of our Company, thereby reducing
the likelihood that you could receive a premium for your common stock in an acquisition.
Failure
to meet the continued listing requirements of the NYSE American may result in the delisting of our common stock, which could result in
lower trading volumes and liquidity, lower prices of our common stock and make it more difficult for us to raise capital.
Our
common stock is listed on the NYSE American, and we are subject to its continued listing requirements, including maintaining certain
share prices and a minimum amount of stockholder’s equity. If we are unable to comply with the NYSE American continued listing
requirements, including its trading price requirements, our common stock may be suspended from trading on and/or delisted from the NYSE
American. Although we have not been notified of any delisting proceedings, there is no assurance that we will not receive such notice
in the future or that we will be able to then comply with NYSE American listing standards. The delisting of our common stock from the
NYSE American may materially impair our stockholders' ability to buy and sell our common stock and could have an adverse effect on the
market price of, and the efficiency of the trading market for, our common stock. In addition, the delisting of our common stock could
significantly impair our ability to raise capital.
Future
issuances of our common stock could lower our stock price and dilute the interests of existing stockholders.
We
may issue additional shares of our common stock in the future, including shares of our common stock in connection with acquisitions,
strategic partnerships or joint ventures that we believe will allow us to complement our growth strategy, increase market share in our
current markets and expand into adjacent markets, broaden our technology and intellectual property, and strengthen our relationships
with distributors and OEMs. Any future issuances of shares of our common stock, including in connection with any future acquisition,
partnership or joint venture, may result in the dilution of existing stockholders to the extent we are required to issue equity securities.
The
issuance of a substantial amount of common stock could have the effect of substantially diluting the interests of our current stockholders.
In addition, the sale of a substantial amount of common stock in the public market, either in the initial issuance or in a subsequent
resale by investors who acquired such common stock in a private placement, could have a material adverse effect on the market price of
our common stock.
In
addition, the $0.75 conversion price for our Series B Convertible Preferred Stock was reduced to $0.3022 due to sales of our common stock
in December 2019, as required by an anti-dilution provision in the certificate of designations governing the Series B Convertible Preferred
Stock. As a result, the number of shares of common stock issuable upon the conversion of the series B preferred stock has increased from
7.5 million to, as of September 30, 2021, 18.7 million shares. If the holders of the Series B Convertible Preferred Stock sell any or
all of the common stock issuable upon conversion of the Series B Convertible Preferred Stock, this could have a material adverse effect
on the market price of our common stock.
Concentration
of ownership of our stock may enable one stockholder or a small number of stockholders to significantly influence matters requiring stockholder
approval.
As
of September 30, 2021, Stillwater Holdings LLC (f/k/a Stillwater LLC) owned approximately 15% of our outstanding voting stock, Flat Creek
Fiduciary Management, as trustee of a trust which the sole member of Stillwater Holdings LLC has investment control, owned approximately
3% of our outstanding voting stock and the sole member of Stillwater Holdings LLC is the investment manager of Rainbow Gate Corporation,
which owned approximately 3% of our outstanding voting stock. Together such stockholders owned approximately 21% of our outstanding voting
stock. As a result, these stockholders, if they act together, may be able to exert a significant degree of influence over matters requiring
stockholder approval, including the election of directors and approval of significant corporate transactions. Further, if these stockholders
act together with another stockholder, Ginola Limited (a stockholder that has common directors with two of our other stockholders: Mount
Union Corp. and Chelsea Trust Company), as of September 30, 2021, they would collectively have represented approximately 25% of our outstanding
voting stock. This concentration of ownership may facilitate or hinder a change of control and might affect the market price of our common
stock. Furthermore, the interests of this concentration of ownership may not always coincide with our interests or the interests of other
stockholders. In nine months ended September 30, 2021, the above stockholders have sold 7.7 million shares of our outstanding common
stock. Future sales of common stock by the above stockholders may negatively impact the price or our common stock.
The
holders of shares of our Series B Convertible Preferred Stock have and may continue to exercise significant influence over us.
Under
the terms of the certificate of designations governing our Series B Convertible Preferred Stock, the Series B Convertible Preferred Stock
generally ranks, with respect to liquidation and dividends, senior to our other securities and, so long as any shares of Series B Convertible
Preferred Stock remain outstanding, the approval of the holders of a majority of the series B convertible preferred stock outstanding
at the time of approval is required in order for us to, among other things, (i) amend, alter or repeal our certificate of incorporation
if such amendment, alteration or repeal adversely affects the powers, preferences or special rights of the Series B Convertible Preferred
Stock; (ii) create any series or class of stock ranking senior as to liquidation rights or dividends with the series B convertible preferred
stock (other than series A senior secured convertible preferred stock, or series A convertible preferred stock); (iii) redeem, or pay
dividends on, any class or series of our capital stock (other than the series A convertible preferred stock); or (iv) so long as there
are holders of at least 577 outstanding shares of series B convertible preferred stock, issue any shares of Series B Convertible Preferred
Stock. The terms of the certificate of designations also provide that so long as any shares of Series B Convertible Preferred Stock are
outstanding, we may not offer, sell or issue, or enter into any agreement, arrangement or understanding to offer, sell or issue, any
common stock or common stock equivalent (other than offerings that are underwritten on a firm commitment basis and registered with the
SEC under the Securities Act) without the approval of holders of a majority of the Series B Convertible Preferred Stock outstanding.
These and other rights granted to holders of the Series B Convertible Preferred Stock enable the holders thereof to exert substantial
control over our affairs and potentially exercise their control in a manner adverse to the interest of our other stockholders. The consent
requirements set forth in the certificate of designations has impaired, and may in the future impair, our ability to raise capital.
The
majority holder of our Series B convertible stock, has prevented, and may in the future prevent, us from entering into significant corporate
transactions that our management and Board have otherwise approved, including certain capital raising transactions.
The
exercise of rights by the majority holder of the Series B convertible preferred stock has impaired, and may in the future impair, our
ability to enter into significant corporate transactions, including certain capital raising transactions. For example, the securities
purchase agreement pursuant to which we sold the Series B convertible preferred stock provides that so long as there are holders of at
least 577 outstanding shares of series B convertible preferred stock and until such date that (i) all shares of our Series B convertible
stock become eligible for resale under Rule 144 without volume restrictions or (ii) a registration statement registering the sale of
such shares becomes effective, unless we obtain the prior written consent of the majority holders, we may not issue or sell any securities
in a capital raising transaction, unless such securities are not and will not be registered under the Securities Act until on or after
the effective date of a registration statement registering the sale of the Series B convertible stock. The majority holder of our Series
B convertible preferred stock, has previously withheld consent to certain capital raises that were proposed by our management and approved
by our Board, most recently in September 2021. As a result, we were unable to proceed with the proposed offerings and raise capital at
the times, at the prices and in the amounts, that our management and our Board deemed most beneficial to the Company. There can be no
assurances that the majority holder of our Series B convertible preferred stock, will not withhold its consent for any future capital
raise we propose.
We
do not intend to pay cash dividends. We last paid a dividend on our capital stock in 2012 and we do not anticipate paying any dividends
in the foreseeable future. Consequently, any gains from an investment in our securities will likely depend on whether the price of our
common stock increases.
We
have not paid dividends on any of our capital stock since 2012. We currently intend to retain our future earnings, if any, to fund the
development and growth of our business. In addition, our asset based lending agreement, or ABL Facility, with Rosenthal & Rosenthal,
which we entered into on December 21, 2016 prohibits us from paying cash dividends on our common stock. As a result, capital appreciation,
if any, of our common stock will be your sole source of gain for the foreseeable future. Consequently, in the foreseeable future, you
will likely only experience a gain from your investment in our securities if the price of our common stock increases.
The
market price of our common stock may be adversely affected by market conditions affecting the stock markets in general, including price
and trading fluctuations on the NYSE American.
Market
conditions may result in volatility in the level of, and fluctuations in, market prices of stocks generally and, in turn, our common
stock and sales of substantial amounts of our common stock in the market, in each case being unrelated or disproportionate to changes
in our operating performance. Concerns over global stability and economic conditions in the United States and abroad have contributed
to the extreme volatility of the markets which may have an effect on the market price of our common stock.
The
substantial number of shares that are or will be eligible for sale could cause our common stock price to decline even if we are successful.
Sales
of significant amounts of common stock in the public market, or the perception that such sales may occur, could materially affect the
market price of our common stock. These sales might also make it more difficult for us to sell equity or equity-linked securities in
the future at a time and price that we deem appropriate. As of September 30, 2021, we have 72,535,631 shares of common stock outstanding
plus (i) options to purchase 3,847,757 shares, (ii) warrants to purchase 9,339,816 shares (iii) convertible preferred stock convertible
into 18,726,009 shares of common stock and (iv) RSU’s to vest of 402,099 shares. If a significant number of our outstanding warrants
or options are exercised, or a significant number of shares of our convertible preferred stock is converted, our stockholders may experience
a substantial dilution in their percentage ownership of our Company.
You
will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase.
Since
the assumed offering price per share of our common stock being offered is substantially higher than the net tangible book value per share
of our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering.
The shares sold in this offering, if any, will be sold from time to time at various prices. After giving effect to the sale of shares
of our common stock in the aggregate amount of $10,000,000 at an assumed offering price of $2.34 per share, the closing sales price of
our common stock on November 17, 2021 on the NYSE American, and after deducting commissions and estimated offering expenses, our as adjusted
net tangible book value as of September 30, 2021 would have been approximately $26.3 million or approximately $0.34 per share. This represents
an immediate increase in net tangible book value of approximately $0.11 per share to our existing stockholders and an immediate dilution
in as adjusted net tangible book value of approximately $2.00 per share to purchasers of our common stock in this offering. See the section
entitled “Dilution” below for a more detailed discussion of the dilution you would incur if you purchase securities in this
offering.
We
will have broad discretion in how we use the net proceeds of this offering. We may not use these proceeds effectively, which could affect
our results of operations and cause our stock price to decline.
We
will have considerable discretion in the application of the net proceeds of this offering. We currently intend to use the net proceeds
from this offering for working capital and general corporate purposes. We have not yet determined the amount of net proceeds to be used
specifically for any particular purpose or the timing of these expenditures. Accordingly, our management will have significant discretion
and flexibility in applying the net proceeds from this offering. Pending any use, as described above, we intend to invest the net proceeds
in high-quality, short-term, interest-bearing securities.
As
a result, investors will be relying upon management’s judgment with only limited information about our specific intentions for
the use of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any
return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that
does not produce income or that loses value.
If
industry or financial analysts do not publish research or reports about our business, or if they issue inaccurate or unfavorable research
regarding our common stock, our share price and trading volume could decline.
Due
to our continued losses and lack of consistent revenue growth, there may be little or no incentive for securities analysts of brokerage
and other financial firms to provide investment coverage of us or to recommend the purchase of our common stock. Any reports that industry
or financial analysts publish about us or our business may influence the trading market for our common stock. We do not control these
analysts, whether they provide investment coverage of us, or the content and opinions included in any of their reports. If any of the
analysts who cover us issues an inaccurate or unfavorable opinion regarding our Company, our stock price would likely decline. In addition,
the stock prices of many companies in the technology industry have declined significantly after those companies have failed to meet,
or significantly exceed, the financial guidance publicly announced by the companies or the expectations of analysts. If our financial
results fail to meet, or significantly exceed, our announced guidance or the expectations of analysts or public investors, analysts could
downgrade our common stock or publish unfavorable research about us. If, after initiating coverage of us and our common stock, one or
more analysts were to cease coverage of our Company or fail to publish reports on us regularly, our visibility in the financial markets
could decrease, which in turn could cause our stock price or trading volume to decline.
A
provision in our certificate of incorporation and by-laws may prevent or delay an acquisition of our Company, which could decrease the
market value of our common stock.
Provisions
of Delaware law, our certificate of incorporation and our by-laws may discourage, delay or prevent a merger, acquisition or other change
in control that stockholders may consider favorable. These provisions may also prevent or delay attempts by stockholders to replace or
remove our current management or members of our Board of Directors. These provisions include:
|
●
|
limitations
on the removal of directors;
|
|
●
|
advance
notice requirements for stockholder proposals and nominations;
|
|
●
|
the
inability of stockholders to act by written consent or to call special meetings;
|
|
●
|
the
ability of our Board of Directors to make, alter or repeal our by-laws; and
|
|
●
|
the
authority of our Board of Directors to issue preferred stock with such terms as our Board
of Directors may determine.
|
In
addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law, which limits business combination
transactions with stockholders of 15% or more of our outstanding voting stock that our Board of Directors has not approved. These provisions
and other similar provisions make it more difficult for stockholders or potential acquirers to acquire us without negotiation. These
provisions may apply even if some stockholders may consider the transaction beneficial to them. As a result, these provisions could limit
the price that investors are willing to pay in the future for shares of our common stock. These provisions might also discourage a potential
acquisition proposal or tender offer, even if the acquisition proposal or tender offer is at a premium over the then current market price
for our common stock.
We
are subject to significant corporate regulation as a public company and failure to comply with all applicable regulations could subject
us to liability or negatively affect our stock price.
As
a publicly traded company, we are subject to a significant body of regulation, including the Sarbanes-Oxley Act of 2002. While we have
developed and instituted a corporate compliance program based on what we believe are the current best practices in corporate governance,
internal and disclosure controls and continue to update this program in response to newly implemented or changing regulatory requirements,
we cannot provide assurance that we are or will be in compliance with all applicable regulations. If we fail to comply with any of these
regulations, we could be subject to a range of regulatory actions, fines or other sanctions or litigation. As part of the review of our
compliance program, we continually review and analyze our internal control over financial reporting for Sarbanes-Oxley Section 404 compliance.
As part of that process we have and in the future may discover material weaknesses or significant deficiencies in our internal control
as defined under standards adopted by the Public Company Accounting Oversight Board that require remediation. In connection with our
2020 year end audit, we identified a significant deficiency in our internal controls over financial reporting related to our failure
to reflect an increase in potentially dilutive common stock equivalents that could be issued as a result of sales of our common stock
under our at-the -market sales agreement priced below our Series B Convertible Preferred Stock conversion rate. This correction had no
impact on any financial statement amounts or earnings per share. Any failure to maintain effective controls or timely effect any necessary
improvement of our internal and disclosure controls could harm operating results or cause us to fail to meet our reporting obligations,
which could affect our ability to remain listed with NYSE American. Ineffective internal and disclosure controls could also cause investors
to lose confidence in our reported financial information, which would likely have a negative effect on the trading price of our securities.
The
common stock offered hereby will be sold in “at-the-market” offerings, and investors who buy shares at different times will
likely pay different prices.
Investors
who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in
their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold,
and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share
sales made at prices lower than the prices they paid.
The
actual number of shares we will issue under the sales agreement, at any one time or in total, is uncertain.
Subject
to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a sales notice to
Wainwright at any time throughout the term of the sales agreement. The number of shares that are sold by Wainwright after delivering
a sales notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Wainwright.
Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period,
it is not possible at this stage to predict the number of shares that will be ultimately issued.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference, contain forward looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, that are based on our management’s
belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected
in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and
involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements.
In
some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,”
“expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology.
These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect our results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in the
section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as
any amendments thereto reflected in subsequent filings with the SEC, and under the heading “Risk Factors” in this prospectus
supplement, the accompanying prospectus and in any free writing prospectus. If one or more of these risks or uncertainties occur, or
if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected
by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus
supplement, the accompanying prospectus, any free writing prospectus and the documents that we reference herein and therein and have
filed as exhibits to the registration statement, of which this prospectus supplement is part, completely and with the understanding that
our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.
Forward-looking
statements include statements concerning, among other things: our ability to generate sufficient cash flows and obtain the additional
financing we need in order to continue as a going concern; our ability to generate additional revenue or secure additional financing
when required, in order to continue our current operations; our ability to manufacture our products on a timely basis and at a competitive
cost; our ability to successfully remediate manufacturing issues that have resulted in production delays and successfully integrate new
equipment on our manufacturing line; our ability to achieve our yield improvement initiatives; our ability to meet our obligations as
they become due over the next twelve months; our needs for additional financing, as well as our ability to obtain such additional financing
on reasonable terms and the interest rate and expense we incur on any debt financing; the impact of the COVID-19 pandemic on our business;
our anticipated cash needs and our estimates regarding our capital requirements; our ability to repay our indebtedness pursuant to our
ABL Facility; changes in demand by original equipment manufacturer, or OEM, customers for advanced microdisplays, limited availability
of products provided by suppliers and foundries, high costs of raw materials, pricing pressure brought by the marketplace or governmental
customers and other factors that impact the commercial, military and consumer markets in which we operate; our ability to maintain our
relationships with customers and vendors; our ability to protect our intellectual property; our ability to successfully develop and market
our products to customers; our ability to generate customer demand for our products in our target markets; the development of our target
markets and market opportunities, including the consumer market; technological developments in our target markets and the development
of alternate, competing technologies in them; the rate of acceptance of augmented reality/virtual reality, or AR/VR, systems and products
in the consumer and commercial marketplace; our potential exposure to product liability claims; our ability to meet customers’
delivery schedules; market pricing for our products and for competing products; the impact of the majority holder of our Series B convertible
stock, being able to prevent us from entering into significant corporate transactions, including certain capital raising transactions;
increasing competition; our ability to comply with the terms of government awards; provisions in certain of our organizational documents,
commercial agreements, government awards, and our military contracts that may prevent or delay an acquisition of, partnership with, or
investment in us and our ability to develop original equipment manufacturer and mass production partnerships; and our ability to maintain
our operations as a result of potential employee, customer and supplier disruptions caused by the COVID-19 pandemic or any resurgences
and quarantine restrictions.
Forward
looking statements contained in this prospectus supplement, the accompanying prospectus or in the documents that we incorporate by reference
herein and therein represent our views only as of the respective dates on which such statements were made. We anticipate that subsequent
events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some
point in the future, we have no current intention of doing so except to the extent required by applicable law. Therefore, these forward-looking
statements do not represent our views as of any date other than the date on which they were made.
USE
OF PROCEEDS
We
may issue and sell shares of our common stock having an aggregate offering price of $10,000,000 from time to time. Because there is no
minimum offering amount required as a condition of this offering, the actual total public offering amount, commissions and net proceeds
to us, if any, are not determinable at this time.
We
intend to use the net proceeds from the securities sold by us in the offering for working capital and general corporate purposes. While
we have estimated the particular uses for the net proceeds of this offering, we cannot specify these uses with certainty. Accordingly,
our management will have significant discretion and flexibility in applying the net proceeds from this offering, and investors will be
relying on the judgment of our management with regard to the use of these net proceeds.
Pending
application of the net proceeds as described above, we intend to invest the net proceeds in high-quality, short-term, interest-bearing
securities.
DILUTION
If
you invest in our common stock, you will experience dilution to the extent of the difference between the assumed public offering price
per share of our common stock and the net tangible book value per share of our common stock immediately after this offering.
Our
net tangible book value as of September 30, 2021, was approximately $16.7 million, or $0.23 per share of our common stock, based upon
the number of shares of our common stock outstanding as of that date. Net tangible book value per share is determined by dividing our
total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September 30, 2021. Dilution
in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock
in this offering and the net tangible book value per share of our common stock immediately after this offering.
After
giving effect to the assumed sale of $10,000,000 of shares of our common stock, at the assumed public offering price of $2.34 per share
of our common stock (the closing price of our common stock on the NYSE American on November 17, 2021), and after deducting the commissions
and estimated offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2021 would have been approximately
$26.3 million, or $0.34 per share. This represents an immediate increase in net tangible book value of $0.11 per share to existing stockholders
and immediate dilution in net tangible book value of $2.00 per share to new investors purchasing our common stock in this offering. The
following table illustrates this change on a per share basis. The as adjusted information below is illustrative only and will adjust
based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares
of our common stock are sold pursuant to this prospectus supplement. The shares sold in this offering, if any, will be sold from time
to time at various prices.
Assumed
public offering price per share
|
|
|
|
|
|
$
|
2.34
|
|
Net
tangible book value per share as of September 30, 2021
|
|
$
|
0.23
|
|
|
|
|
|
Increase
in net tangible book value per share attributable to this offering
|
|
$
|
0.11
|
|
|
|
|
|
As
adjusted net tangible book value per share as of September 30, 2021 after giving effect to this offering
|
|
|
|
|
|
$
|
0.34
|
|
Dilution
in net tangible book value per share to investors in this offering
|
|
|
|
|
|
$
|
2.00
|
|
Each
$0.25 increase (decrease) in the assumed public offering price of $2.34 per share (the closing price of our common stock on the NYSE
American on November 17, 2021) would increase (decrease) the as adjusted net tangible book value by $0.01 per share and would increase
(decrease) the dilution per share to new investors by approximately $0.01 after deducting commissions and estimated offering expenses
payable by us for this offering.
The
foregoing table and discussion is based on 72,535,631 shares outstanding as of September 30, 2021 and excludes:
|
●
|
3,847,757
shares of our common stock issuable upon the exercise of stock options outstanding as of
September 30, 2021, at a weighted average exercise price of $1.92 per share;
|
|
●
|
402,099
shares of our common stock underlying Restricted Stock Units, or RSU’s that are issuable
subject to the satisfaction of certain time-based service criteria;
|
|
●
|
103,048
shares of our common stock underlying RSU’s that are issuable subject to the achievement
of certain financial targets over a performance period, and the satisfaction of certain time
based service criteria;
|
|
●
|
18,726,009
shares of common stock issuable upon conversion of our outstanding Series B Convertible Preferred
Stock; and
|
|
●
|
3,000,000
shares of our common stock issuable upon the exercise of warrants issued in April 2019 and
outstanding as of September 30, 2021, at an exercise price of $0.78 per share; 1,680,447
shares of our common stock issuable upon the exercise of warrants issued in August 2016 and
outstanding as of September 30, 2021, at an exercise price of $2.60 per share; 100,000 shares
of our common stock issuable upon the exercise of warrants issued in March 2017 and outstanding
as of September 30, 2021, at an exercise price of $2.25 per share, 1,650,000 shares of our
common stock issuable upon the exercise of warrants issued in May 2017 and outstanding as
of September 30, 2021, at an exercise price of $2.45 per share; and 2,909,369 shares of our
common stock issuable upon the exercise of warrants issued in January 2018 and outstanding
as of September 30, 2021, at an exercise price of $1.55 per share.
|
The
above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options to purchase
our common stock or outstanding warrants to purchase shares of our common stock. The exercise of outstanding options and warrants having
an exercise price less than the assumed offering price will increase dilution to new investors. In addition, we may choose to raise additional
capital depending on market conditions, our capital requirements and strategic considerations, even if we believe we have sufficient
funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible
debt securities, the issuance of these securities could result in further dilution to our stockholders.
PLAN
OF DISTRIBUTION
We
have entered into a sales agreement with Wainwright, under which we may issue and sell from time to time shares of our common stock having
an aggregate offering price of not more than $10,000,000 through Wainwright as our sales agent. Sales of the common stock, if any, will
be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under
the Securities Act. If we and Wainwright agree on any method of distribution other than sales of shares of our common stock into the
Nasdaq Capital Market or another existing trading market in the United States at market prices, we will file a further prospectus supplement
providing all information about such offering as required by Rule 424(b) under the Securities Act.
Wainwright
will offer our common stock at prevailing market prices subject to the terms and conditions of the sales agreement as agreed upon by
us and Wainwright. We will designate the number of shares which we desire to sell, the time period during which sales are requested to
be made, any limitation on the number of shares that may be sold in one day and any minimum price below which sales may not be made.
Subject to the terms and conditions of the sales agreement, Wainwright will use its commercially reasonable efforts consistent with its
normal trading and sales practices and applicable law and regulations to sell on our behalf all of the shares of common stock requested
to be sold by us. We or Wainwright may suspend the offering of the common stock being made through Wainwright under the sales agreement
upon proper notice to the other party.
Settlement
for sales of common stock will occur on the second business day or such shorter settlement cycle as may be in effect under Exchange Act
Rule 15c6-1 from time to time, following the date on which any sales are made, or on some other date that is agreed upon by us and Wainwright
in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated
in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Wainwright
may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.
We
will pay Wainwright in cash, upon each sale of our shares of common stock pursuant to the sales agreement, a commission equal to 3.0%
of the gross proceeds from each sale of shares of our common stock. Because there is no minimum offering amount required as a condition
to this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.
Pursuant to the terms of the sales agreement, we agreed to reimburse Wainwright for the documented fees and costs of its legal counsel
reasonably incurred in connection with entering into the transactions contemplated by the sales agreement in an amount not to exceed
$50,000 in the aggregate. We estimate that the total expenses of the offering payable by us, excluding commissions payable to Wainwright
under the sales agreement, will be approximately $60,000. We will report at least quarterly the number of shares of common stock sold
through Wainwright under the sales agreement, the net proceeds to us and the compensation paid by us to Wainwright in connection with
the sales of common stock.
In
connection with the sales of common stock on our behalf, Wainwright will be deemed to be an “underwriter” within the meaning
of the Securities Act, and the compensation paid to Wainwright will be deemed to be underwriting commissions or discounts. We have agreed
in the sales agreement to provide indemnification and contribution to Wainwright against certain liabilities, including liabilities under
the Securities Act.
The
offering of our shares of common stock pursuant to the sales agreement will terminate upon the earlier of the (i) sale of all of our
shares of common stock provided for in this prospectus supplement and (ii) termination of the sales agreement as permitted therein.
Wainwright
and its affiliates may in the future provide various investment banking and other financial services for us and our affiliates, for which
services they may in the future receive customary fees. To the extent required by Regulation M, Wainwright will not engage in any market
making activities involving our shares of common stock while the offering is ongoing under this prospectus supplement. This summary of
the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. We will file
a copy of the sales agreement with the SEC on a Current Report on Form 8-K within the time required by the Exchange Act.
This
prospectus in electronic format may be made available on a website maintained by Wainwright and Wainwright may distribute this prospectus
electronically.
LEGAL
MATTERS
The
validity of the securities offered hereby has been passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Ellenoff Grossman
& Schole LLP, New York, New York is representing the sales agent in connection with this offering.
EXPERTS
The
consolidated financial statements of eMagin Corporation as of December 31, 2020 and 2019 and for each of the years in the two-year period
ended December 31, 2020 incorporated in this Prospectus Supplement by reference from the eMagin Corporation Annual Report on Form 10-K
for the year ended December 31, 2020 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in
their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph relating to going concern),
incorporated herein by reference, and have been incorporated in this Prospectus Supplement and Registration Statement in reliance upon
such report and upon the authority of such firm as experts in accounting and auditing.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and file annual, quarterly
and current reports, proxy statements and other information with the SEC. You can request copies of these documents by writing to the
SEC and paying a fee for the copying cost. The SEC also maintains an Internet site that contains reports, proxy statements and other
information about issuers, like us, who file electronically with the SEC. The address of the SEC’s web site is http://www.sec.gov.
Our common stock is listed for trading on the NYSE American under the symbol “EMAN.”
We
have filed with the SEC a registration statement on Form S 3 (File No. 333-239441) under the Securities Act of 1933, as amended, or the
Securities Act, with respect to the securities offered by this prospectus supplement and the accompanying prospectus. This prospectus
supplement and the accompanying prospectus filed as part of the registration statement do not contain all the information set forth in
the registration statement and its exhibits and schedules. For further information about us, this offering and our common stock, you
may refer to the registration statement and to its exhibits and schedules as well as the documents described herein or incorporated herein
by reference. You can review and copy these documents, without charge, at the public reference facilities maintained by the SEC or on
the SEC’s website as described above or you may obtain a copy from the SEC upon payment of the fees prescribed by the SEC.
We
maintain a website at www.emagin.com. The information contained on or accessible through our website is not incorporated by reference
into this prospectus supplement or the accompanying prospectus and you should not consider information on or accessible through our website
to be part of this prospectus supplement or the accompanying prospectus.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information that we file with it, which means that we can disclose important
information to you by referring you to those documents instead of having to repeat the information in this prospectus supplement and
the accompanying prospectus. The information incorporated by reference is an important part of this prospectus supplement and accompanying
prospectus. To the extent that any statement that we make in this prospectus supplement is inconsistent with the statements made in the
accompanying prospectus or the information incorporated by reference, the statements made in the accompanying prospectus are deemed modified
or superseded by the statements made in this prospectus supplement, while information that we file later with the SEC will automatically
update and supersede this information. We incorporate by reference into this prospectus supplement the documents listed below and any
future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus
supplement but prior to the termination of the offering of the securities covered by this prospectus supplement and accompanying prospectus
(other than information deemed furnished pursuant to Items 2.02 and 7.01 of Form 8-K). The documents we are incorporating by reference
are:
|
●
|
Our
Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 19, 2021;
|
|
●
|
Our
Quarterly Reports on Form 10-Q for the for the quarters ended March 31, 2021, June 30, and September 30, 2021, filed with the SEC on
May 13, 2021, August 12, 2021, and November 12, respectively;
|
|
●
|
Our
Current Report on Form 8-K filed with the SEC on June 11, 2021;
|
|
●
|
Information
contained in our definitive Proxy Statement on Schedule 14A relating to our annual meeting of stockholders, filed with the SEC on April
29, 2021, that is responsive to Part III of Form 10-K; and
|
|
●
|
The
description of our common stock contained in our Registration Statement on Form 8-A (File No. 001-15751), filed with the SEC on May 12,
2010 (including any further amendment or reports filed with the SEC for the purpose of updating such description).
|
We
will provide without charge to each person, including any beneficial owner, to whom this prospectus supplement is delivered, upon written
or oral request, a copy of any or all documents that are incorporated by reference into this prospectus supplement, but not delivered
with the prospectus supplement, other than exhibits to such documents unless such exhibits are specifically incorporated by reference
into the documents that this prospectus supplement incorporates. You should direct written requests to:
Andrew
G. Sculley, Chief Executive Officer
eMagin Corporation
700 South Drive, Suite 201
Hopewell Junction, NY 12533
(845)-838-7900
The information in this prospectus is
not complete and may be changed. We may not sell or accept an offer to buy these securities until the registration statement filed with
the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting
offers to buy these securities in any jurisdiction where such offer or sale is not permitted.
Subject to Completion,
Dated June 25, 2020
PROSPECTUS
$80,000,000
Common Stock, Preferred Stock, Debt Securities,
Warrants or Units
From time to time, we may offer up to $80,000,000 of any combination
of the securities described in this prospectus, either individually or in units. Each time we offer securities, we will provide the
specific terms of the securities offered in one or more supplements to this prospectus. We may also authorize one or more free writing
prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus
may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus
supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities
being offered.
This prospectus also may be used in connection with the issuance of
up to 8,033,500 shares of our common stock (the “Warrant Shares”) upon exercise of certain of our outstanding warrants
(the “Warrants”). Such Warrants and Warrant Shares were registered under our Registration Statement on Form S-3 (File
No. 333-218838), filed with the Securities and Exchange Commission on June 20, 2017 and declared effective on July 11, 2017 (the
“Prior Registration Statement”), as more fully described herein under the heading “Description of Capital Stock—Warrants.”
The securities offered by this prospectus may be sold directly by us
to investors, through agents designated from time to time or to or through underwriters or dealers. We will set forth the names of any
underwriters or agents and any applicable fees, commissions, discounts and over-allotments in an accompanying prospectus supplement. For
additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus
and in the applicable prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from
such sale will also be set forth in a prospectus supplement.
Our common stock is traded on NYSE American under the symbol “EMAN.”
On June 24, 2020, the last reported sale price of our common stock on NYSE American was $0.82 per share. The applicable prospectus
supplement will contain information, where applicable, as to any other listing, if any, on NYSE American or any securities market or other
exchange of the securities covered by the applicable prospectus supplement.
Investing in our securities involves a high degree of risk.
You should review carefully the risks and uncertainties referenced under the heading “Risk Factors” on page 4 of
this prospectus as well as those contained in the applicable prospectus supplement and any related free writing prospectus,
and in the other documents that are incorporated by reference into this prospectus.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation
to the contrary is a criminal offense.
The date of this prospectus is June 25, 2020.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement on
Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, utilizing a “shelf” registration
process. Under this shelf registration process, we may offer shares of our common stock and preferred stock, various series of
warrants to purchase common stock or preferred stock and debt securities, either individually or in units, in one or more offerings,
up to a total dollar amount of $80,000,000. This prospectus provides you with a general description of the securities we may
offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will
contain more specific information about the specific terms of the offering. This prospectus also relates to the issuance of up to
8,033,500 Warrant Shares upon exercise of certain of our outstanding Warrants. The Warrants and the Warrant Shares were
registered under the Prior Registration Statement. We may also authorize one or more free writing prospectuses to be provided
to you that may contain material information relating to these offerings. Each such prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this
prospectus or in documents incorporated by reference into this prospectus. We urge you to carefully read this prospectus, any
applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by
reference as described under the headings “Where You Can Find Additional Information” and “Incorporation of
Certain Information by Reference,” including the risks referred to under the heading “Risk Factors” in this
prospectus, in the applicable prospectus supplement and any related free writing prospectus, and in the other documents that are
incorporated by reference into this prospectus, before buying any of the securities being offered.
You should rely only on the information contained or incorporated by
reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We have not authorized anyone
to provide you with different information in addition to or different from that contained in this prospectus, any applicable prospectus
supplement and any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to
represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that
we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus is an offer
to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should
assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate
only as of the date on the front of the document and that any information incorporated by reference is accurate only as of the date of
the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or
any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operating and prospects
may have changed materially since those dates.
This prospectus contains summaries of certain provisions contained
in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries
are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed
or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain
copies of those documents as described below under the heading “Where You Can Find Additional Information.”
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We post on our public website (www.emagin.com) our Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably
practicable after we electronically file such material with, or furnish it to, the SEC. Our website and the information contained on that
site, or connected to that site, are not incorporated into and are not a part of this prospectus.
You can find, copy and inspect information we file with the SEC at
the SEC’s public reference room, which is located at 100 F Street, N.E. Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330
for more information about the operation of the SEC’s public reference room. You can also review our electronically filed reports
and other information that we file with the SEC on the SEC’s website at http://www.sec.gov.
This prospectus is part of a registration statement that we filed with
the SEC. The registration statement contained more information than this prospectus regarding us and the securities, including exhibits
and schedules. You can obtain a copy of the registration statement from the SEC at any address listed above or from the SEC’s website.
You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiary
and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement
or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should
review the complete document to evaluate these statements.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to “incorporate by reference” the information
we file with it, which means that we can disclose important information to you by referring you to those documents instead of having
to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus,
and later information that we file with the SEC will automatically update and supersede this information. We incorporate by reference
the documents listed below that we have filed with the SEC:
|
●
|
description
of our common stock contained in our registration statement on Form 8-A (File No. 001-15751), filed with the SEC on May 12, 2010
(including any further amendment or reports filed with the SEC for the purpose of updating such description);
|
|
●
|
our
Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the SEC on March 11, 2020;
|
|
●
|
our
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 filed with the SEC on May 14, 2020;
|
|
●
|
Our
definitive Proxy Statement on Schedule 14A relating to our annual meeting of stockholders, filed with the SEC on April 29, 2020
(solely with respect to those portions incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December
31, 2019); and
|
|
●
|
Our
Current Reports on Form 8-K filed with the SEC on January 28, 2020, February 13, 2020, March 10, 2020 and May 14, 2020 (except
that, with respect to each of the foregoing Current Reports, any portions thereof which are furnished and not filed shall not be deemed
incorporated by reference into this prospectus supplement).
|
We also incorporate by reference into this prospectus all documents
(other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related
to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the
date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration
statement, or (ii) after the date of this prospectus until we sell all of the shares covered by this prospectus or the sale of shares
by us pursuant to this prospectus is terminated.
A statement contained in a document incorporated by reference into
this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained
in this prospectus, any prospectus supplement or in any other subsequently filed document which is also incorporated in this prospectus
modifies or replaces such statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this prospectus. You should not assume that the information in this prospectus or in the documents incorporated
by reference is accurate as of any date other than the date on the front of this prospectus or those documents.
You may request a copy of these documents, orally or in writing, which
will be provided to you at no cost by contacting:
Andrew G. Sculley, Chief Executive Officer
eMagin Corporation
700 South Street, Suite 201
Hopewell Junction, NY 12533
(845) 838-7900
FORWARD-LOOKING STATEMENTS
This prospectus, including the documents that we incorporate by reference,
contains forward-looking statements that are based on our management’s belief and assumptions and on information currently
available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these
statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed or implied by these forward-looking statements.
In some cases, you can identify forward-looking statements by terminology
such as “may,” “will,” “should,” “expects,” “intends,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue”
or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance
on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases,
beyond our control and which could materially affect our results. Factors that may cause actual results to differ materially from current
expectations include, among other things, those listed in the section entitled “Risk Factors” and elsewhere in this Report.
If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results
may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee
of future performance. You should read this Report and the documents that we reference in this Report and have filed with the Securities
and Exchange Commission, or the SEC, as exhibits to this Report, completely and with the understanding that our actual future results
may be materially different from any future results expressed or implied by these forward-looking statements:
|
●
|
our
ability to generate sufficient cash flows and obtain the additional financing we need in order to continue as a going concern;
|
|
●
|
our
ability to generate additional revenue or secure additional external financing when, or if, required, in order to continue our current
operations;
|
|
●
|
our
ability to manufacture our products on a timely basis and at a competitive cost;
|
|
●
|
our
ability to successfully remediate manufacturing issues that have resulted in production delays and successfully integrate new equipment
on our manufacturing line;
|
|
●
|
our
ability to achieve our yield improvement initiatives;
|
|
●
|
our
ability to meet our obligations as they become due over the next twelve months;
|
|
●
|
our
needs for additional financing, as well as our ability to obtain such additional financing on reasonable terms and the interest rate
and expense we incur on any debt financing;
|
|
●
|
our
anticipated cash needs and our estimates regarding our capital requirements;
|
|
●
|
our
ability to maintain our relationships with customers and vendors;
|
|
●
|
our
ability to protect our intellectual property;
|
|
●
|
our
ability to successfully develop and market our products to customers;
|
|
●
|
our
ability to generate customer demand for our products in our target markets;
|
|
●
|
the
development of our target markets and market opportunities, including the consumer market;
|
|
●
|
technological
developments in our target markets and the development of alternate, competing technologies in them;
|
|
●
|
the
rate of acceptance of AR/VR systems and products in the consumer and commercial marketplace;
|
|
●
|
our
potential exposure to product liability claims;
|
|
●
|
our
ability to meet customers’ delivery schedules;
|
|
●
|
market
pricing for our products and for competing products;
|
|
●
|
the
concentration of a significant ownership percentage in our Company in a relatively small number of stockholders and the ability of one
or more of such stockholders to exert substantial control over our affairs;
|
|
●
|
changes
in demand by original equipment manufacturer (“OEM”) customers for advanced microdisplays, limited availability of suppliers
and foundries, high costs of raw materials, pricing pressure brought by the marketplace or governmental customers and other factors that
impact the commercial, military and consumer markets in which we operate;
|
|
●
|
increasing
competition;
|
|
●
|
provisions
in certain of our organizational documents, commercial agreements and our military contracts that may prevent or delay an acquisition
of, partnership with, or investment in, our Company and our ability to develop original equipment manufacturer and mass production partnerships;
|
|
●
|
our
ability to maintain our operations as a result of potential employee, customer and supplier disruptions caused by the COVID-19 pandemic;
and
|
|
●
|
our
efforts to settle purchase commitments remaining from our consumer night vision business.
|
Forward-looking statements contained in this prospectus, any applicable
prospectus supplement or free writing prospectus or in the documents that we reference herein and therein represents our views only as
of the respective dates on which such statements were made. We anticipate that subsequent events and developments may cause our views
to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention
of doing so except to the extent required by applicable law. Therefore, these forward-looking statements do not represent our views as
of any date other than the date on which they were made.
SUMMARY
This summary highlights selected information from this prospectus or
incorporated by reference in this prospectus, and does not contain all of the information that you need to consider in making your investment
decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus,
including the risks of investing in our securities referred to under the heading “Risk Factors” in this prospectus and contained
in the applicable prospectus supplement and any related free writing prospectus, and in the other documents that are incorporated by reference
into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial
statements, and the exhibits to the registration statement of which this prospectus is a part.
Unless otherwise mentioned or unless the context requires otherwise,
throughout this prospectus, any applicable prospectus supplement and any related free writing prospectus, the words ‘‘eMagin
Corporation,” “eMagin,” “the Company,” “we,” “us,” and “our company”
or similar references refer to eMagin Corporation and its wholly owned subsidiary, Virtual Vision, Inc.; and the term “securities”
refers collectively to our common stock, preferred stock, warrants to purchase common stock or preferred stock, debt securities, or any
combination of the foregoing securities.
This prospectus, and the information incorporated herein by reference,
includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included
or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus are the
property of their respective owners.
Our Company
We design, develop, manufacture and market organic light emitting diode,
or OLED miniature displays, which we refer to as OLED-on-silicon microdisplays, virtual imaging products that utilize OLED microdisplays,
and related products. We also perform research in the OLED field. Our virtual imaging products integrate OLED technology with silicon
chips to produce high-resolution microdisplays which, when viewed through a magnifying headset, create virtual images that appear comparable
in size to that of a computer monitor or a large-screen television. Our products enable our original equipment manufacturer, or OEM, customers
in the military and commercial markets to develop and market improved or new electronic products.
We believe that our OLED microdisplays offer a number of significant
advantages over comparable liquid crystal microdisplays, including higher contrast, greater power efficiency, less weight, more compact
size, and negligible image smearing. Using our active matrix OLED technology, many computer and electronic system functions can be built
directly into the OLED microdisplay silicon backplane, resulting in compact, high resolution and power efficient systems. Already proven
in military and commercial systems, our product portfolio of OLED microdisplays deliver high-resolution, virtual images that perform effectively
even in extreme temperatures and high-vibration conditions.
Our OEM customers incorporate our OLED displays in a variety of products
including, military aviation helmets, military weapons sights and targeting systems, night vision and thermal imaging devices, training
and simulation, visualization for ocular surgery, mobile ultrasound, and augmented reality applications.
We believe our technology, intellectual property portfolio and position
in the marketplace give us a leadership position in OLED and OLED-on-silicon microdisplay technology. We have an intellectual property
portfolio that includes 35 U.S. patents and 18 pending U.S. patent applications (one of which have received a Notice of Allowance), and
have over 20 years of manufacturing know-how and other proprietary technologies to create our high performance OLED microdisplays. We
also have 3 issued foreign patents and 21 foreign filings. We believe that we are one of only a few companies to market and produce significant
quantities of high resolution, small molecule OLED-on-silicon microdisplays.
We also believe that our direct patterning (“dPd”) technology,
which we introduced during 2018, gives us an advantage over other OLED microdisplays because it allows us to produce microdisplays with
the high brightness required for VR and AR and certain military applications. Traditional OLED microdisplays utilize white emitting OLED
with color filters that lessen the intensity of emitted light by as much as 80%, significantly reducing brightness. Microdisplays manufactured
by dPd technology do not require color filters to achieve color variations and allow for the application of more efficient OLED structures
which achieve higher brightness. dPd also allows for much lower power and longer life when run at the same luminance of a color filter
display.
We were formed in March 2000, through the merger of Fashion
Dynamics Corporation, and FED Corporation, a developer and manufacturer of optical systems and microdisplays for use in the electronics
industry. Simultaneous with this merger, we changed our name to eMagin Corporation. We are incorporated in the state of Delaware.
The address of our principal executive offices is 700 South Street,
Suite 201, Hopewell Junction, NY 12533 and our telephone number is (845) 838-7900. Our website address is www.emagin.com. We
do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information
on, or that can be accessed through, our website as part of this prospectus.
The Securities We May Offer
We may offer shares of our common stock and preferred stock, various
series of warrants to purchase common stock or preferred stock and debt securities, in one or more series, as either senior or subordinated
debt or as senior or subordinated convertible debt, either individually or in units, with a total value of up to $80,000,000 from time
to time under this prospectus at prices and on terms to be determined at the time of any offering. This prospectus provides you with a
general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide
a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities.
The prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have
incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and
described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.
We may sell the securities directly to investors or to or through agents,
underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase
of securities. If we do offer securities to or through agents or underwriters, we will include in the applicable prospectus supplement:
|
●
|
the
names of those agents or underwriters;
|
|
●
|
applicable
fees, discounts and commissions to be paid to them;
|
|
●
|
details
regarding over-allotment options, if any; and
|
|
●
|
the
net proceeds to us.
|
Common Stock. We may issue shares of our common
stock from time to time. Holders of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.
Holders of our common stock do not have cumulative voting rights in the election of directors. Subject to the preferences that may be
applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends, if any,
as may be declared by our Board of Directors out of funds legally available therefor. Upon the liquidation, dissolution, or
winding up of our company, holders of common stock are entitled to share ratably in all of our assets which are legally available
for distribution after payment of all debts and other liabilities and liquidation preference of any outstanding preferred stock.
Preferred Stock. We may issue shares of our
preferred stock from time to time, in one or more series. Our Board of Directors will determine the rights, preferences and
privileges of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, including
dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund
terms and the number of shares constituting any series or the designation of any series.
If we sell any series of preferred stock under this prospectus, we
will fix the rights, preferences and privileges of the preferred stock of such series, as well as any qualifications, limitations or restrictions
thereon, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation
that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. We urge
you to read the applicable prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to
the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable
series of preferred stock.
Debt Securities. We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. In this prospectus, we have
summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement and any
free writing prospectus that we may authorize to be provided to you related to the particular series of debt securities being offered,
as well as the complete indenture that contains the terms of the debt securities. We will file as exhibits to the registration statement
of which this prospectus is a part, the form of indenture and any supplemental agreements that describe the terms of the series of debt
securities we are offering before the issuance of the related series of debt securities.
We may evidence each series of debt securities by indentures we will
issue. Debt securities may be issued under an indenture that we enter into with a trustee. We will indicate the name and address of the
trustee, if applicable, in the prospectus supplement relating to the particular series of debt securities being offered.
Warrants. We may issue warrants from time to time, in one or
more series, for the purchase of common stock and/or preferred stock. We may issue warrants independently or together with common stock
and/or preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus,
we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement and any
free writing prospectus that we may authorize to be provided to you related to the particular series of warrants being offered, as well
as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and
forms of warrant certificates containing the terms of the warrants being offered will be filed as exhibits to the registration statement
of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.
We will evidence each series of warrants by warrant certificates that
we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate
the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being
offered.
Units. We may issue units from time to time, in one or
more series, consisting of common stock, preferred stock, debt securities and/or warrants for the purchase of common stock and/or preferred
stock in any combination. In this prospectus, we have summarized certain general features of the units. We urge you, however, to read
the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series
of units being offered, as well as the complete unit agreement that contains the terms of the units. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit
agreement and any supplemental agreements that describe the terms of the series of units we are offering before the issuance of the related
series of units.
We will evidence each series of units by unit certificates that we
will issue. Units may be issued under a unit agreement that we enter into with a unit agent. We will indicate the name and address of
the unit agent, if applicable, in the prospectus supplement relating to the particular series of units being offered.
Warrant Shares. This prospectus also relates to the
issuance of the Warrant Shares upon exercise of certain of our outstanding Warrants. Such Warrants and Warrant Shares
were previously registered under the Prior Registration Statement. The material terms of the outstanding Warrants are
summarized herein, which summaries are qualified in their entirety by reference to the forms of warrants and warrant agreements
incorporated by reference as exhibits to the registration statement of which this prospectus is a part. To the extent that the
terms of the offering and issuance of the Warrant Shares materially differs from those terms disclosed in this prospectus, we may
provide you with a prospectus supplement that will contain specific information about the terms of such offering.
RISK FACTORS
An investment in our securities involves a high degree of risk. In
addition to the other information included in, or incorporated by reference into, this prospectus, the applicable prospectus supplement
and any related free writing prospectus, you should carefully consider the risks and uncertainties set forth under the heading “risk
factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 11, 2020 and
in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC on May 14, 2020 which are
incorporated by reference in this prospectus, as the same may be updated from time to time by our future filings under the Securities Exchange
Act of 1934, as amended, or the Exchange Act (including by the filing of Current Reports on Form 8-K), when determining whether or not to
purchase the securities offered under this prospectus and the prospectus supplement. If any of these risks were to occur, our business,
financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and
you could lose all or part of your investment. The risks and uncertainties we describe are not the only ones we face. Additional
risks not presently known to us or that we currently deem immaterial may also impair our business operations and trading price of
our common stock.
USE OF PROCEEDS
Except as described in any prospectus supplement or in any related
free writing prospectus that we may authorize to be provided to you, the net proceeds received by us from our sale of the securities
described in this prospectus will be added to our general funds and will be used for our general corporate purposes. From time to time,
we may engage in additional public or private financings of a character and amount which we may deem appropriate.
DILUTION
If there is a material dilution of the purchasers’ equity interest
from the sale of common equity securities offered under this prospectus, we will set forth in any prospectus supplement the following
information regarding any such material dilution of the equity interests of purchasers’ securities in an offering under this prospectus:
|
●
|
the
net tangible book value per share of our equity securities before and after the offering;
|
|
●
|
the
amount of the increase in such net tangible book value per share attributable to the cash payments made by the purchasers in the offering;
and
|
|
●
|
the
amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.
|
PLAN OF DISTRIBUTION
We may sell the securities from time to time pursuant to underwritten
public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters
or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:
|
●
|
at
a fixed price or prices, which may be changed;
|
|
●
|
at
market prices prevailing at the time of sale;
|
|
●
|
at
prices related to such prevailing market prices; or
|
Each time we offer and sell securities, we will provide a prospectus
supplement that will set forth the terms of the offering of the securities, including:
|
●
|
the
name or names of the underwriters, if any;
|
|
●
|
the
purchase price of the securities and the proceeds we will receive from the sale;
|
|
●
|
any
over-allotment options under which underwriters may purchase additional securities;
|
|
●
|
any
agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation;
|
|
●
|
any
public offering price;
|
|
●
|
any
discounts or concessions allowed or re-allowed or paid to dealers; and
|
|
●
|
any
securities exchange or market on which the securities may be listed.
|
If underwriters are used in the sale, they will acquire the securities
for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or
at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the
conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates
represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated
to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any
public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may change from time to time. We may use
underwriters with whom we or they have a material relationship. The prospectus supplement, naming the underwriter, will describe the nature
of any such relationship.
We may sell securities directly or through agents we or they designate
from time to time. The prospectus supplement will name any agent involved in the offering and sale of securities and any commissions we
will pay to them. Unless the prospectus supplement states otherwise, any agent will be acting on a best-efforts basis for the period of
its appointment.
We may authorize agents or underwriters to solicit offers by certain
purchasers to purchase securities from us or them at the public offering price set forth in the prospectus supplement pursuant to delayed
delivery contracts providing for payment and delivery on a specified date in the future. The prospectus supplement will set forth the
conditions to these contracts and any commissions we must pay for solicitation of these contracts.
We may engage in at the market offerings into an existing trading market
in accordance with Rule 415(a)(4) under the Securities Act.
We may provide agents and underwriters with indemnification against
civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters
may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the
ordinary course of business.
All securities we may offer, other than common stock, will be new issues
of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to
do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any
securities.
Any underwriter may engage in over-allotment, stabilizing transactions,
short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales
in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security
so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve
purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed,
to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally
sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price
of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any
time.
Any underwriters that are qualified market makers on NYSE American
LLC, or NYSE American, may engage in passive market making transactions in the common stock on NYSE American in accordance with Regulation M
under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the
common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security;
if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then
be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
DESCRIPTION OF CAPITAL STOCK
General
Our authorized capital stock consists of 200,000,000 shares of common
stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share. As of June 24, 2020,
there were 61,215,265 shares of our common stock outstanding, 5,659 shares of our preferred stock outstanding, warrants issued in
December 2015 to purchase 383,500 shares of our common stock, warrants issued in August 2016 to purchase 2,947,949 shares of our common
stock outstanding, warrants issued in March 2017 to purchase 100,000 shares of our common stock outstanding, warrants issued in
May 2017 to purchase 1,650,000 shares of our common stock outstanding, warrants issued in January 2018 to purchase 4,004,324 shares of
our common stock outstanding and warrants issued in April 2019 to purchase 6,210,000 shares of our common stock outstanding.
The following summary description of our capital stock is based on
the provisions of our amended and restated certificate of incorporation, amended and restated bylaws, outstanding warrants and the applicable
provisions of the Delaware General Corporation Law. This summary does not purport to be complete and is qualified entirely by reference
to the applicable provisions of our amended and restated certificate of incorporation, amended and restated bylaws, outstanding warrants
and the Delaware General Corporation Law. For information on how to obtain copies of our amended and restated certificate of incorporation
and amended and restated bylaws, which are exhibits to the registration statement of which this prospectus is a part, see “Where
You Can Find Additional Information” and “Incorporation of Certain Information by Reference.”
Common Stock
We may issue shares of our common stock from time to time. Holders
of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Holders of our common stock
do not have cumulative voting rights in the election of directors. Subject to the preferences that may be applicable to any then outstanding
preferred stock, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors
out of funds legally available therefor. Upon the liquidation, dissolution, or winding up of our company, holders of common stock are
entitled to share ratably in all of our assets which are legally available for distribution after payment of all debts and other liabilities
and liquidation preference of any outstanding preferred stock. There are no sinking fund provisions applicable to our common stock. Holders
of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of
common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that
we may designate and issue in the future. The outstanding shares of common stock are validly issued, fully paid and non-assessable.
Warrants
As of June 24, 2020, we had warrants outstanding and exercisable
for 15,265,773 shares of our common stock. Below is a summary of our outstanding warrants.
2015 Warrants
The following description of our 2015 warrants is subject to, and qualified
in its entirety by, the form of 2015 warrant, which filed as an exhibit to our current report on Form 8-K filed with the SEC on December
18, 2015. You should review a copy of the form of 2015 warrant for a complete description of the terms and conditions applicable
to the 2015 warrants. The offering and sale of the 2015 warrants, and the shares of common stock underlying the 2015 warrants,
were registered under the Prior Registration Statement.
Term. The 2015 warrants became exercisable commencing six months
after the date of issuance, for five years, but not thereafter.
Exercise Price. The exercise price of the 2015 warrants is $2.05
per share. The exercise price and number of shares of our common stock issuable upon the exercise of the 2015 warrants is subject
to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization
or similar transaction.
Exercisability. The 2015 warrants became exercisable commencing
six months after the date of issuance and are exercisable at any time during the applicable term of the 2015 warrant. The 2015 warrants
are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of shares of our common stock purchased upon such exercise. If there is no effective registration
statement registering the issuance of the shares underlying the 2015 warrants, then the 2015 warrants may be exercised by means of
a cashless exercise.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the 2015 warrants. As to any fraction of a share which the holder would otherwise
be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the exercise price of the 2015 warrant or round up to the next whole share.
Transferability. Subject to applicable laws, the 2015 warrants
may be transferred at the option of the holder upon surrender of the 2015 warrants to us together with the appropriate instruments
of transfer.
Authorized Shares. During the period the 2015 warrants are outstanding,
we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance of shares
of common stock underlying the 2015 warrants upon the exercise of the 2015 warrants.
Fundamental Transactions. In the event of any fundamental transaction,
as described in the 2015 warrants and generally including any merger with or into another entity, sale of all or substantially all
of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of a 2015
warrant the holder shall have the right to receive as alternative consideration, for each share of our common stock that would have
been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common
stock of the successor or acquiring corporation or of us, if we are the surviving corporation, and any additional consideration receivable
upon or as a result of such transaction by a holder of the number of shares of our common stock for which the 2015 warrant is exercisable
immediately prior to such event.
Right as a Stockholder. Except as otherwise provided in the
2015 warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the 2015 warrants do not
have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their 2015 warrants.
Waivers and Amendments. The terms of any 2015 warrant may be
amended or waived with our written consent and the written consent of the holder of such 2015 warrant.
Beneficial Ownership Limitation. Subject to limited exceptions,
a holder of 2015 warrants does not have the right to exercise any portion of its warrants if the holder, together with its affiliates,
would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect
to such exercise.
2016 Warrants
The following description of our 2016 warrants is subject to, and qualified
in its entirety by, the form of 2016 warrant, which filed as an exhibit to our current report on Form 8-K filed with the SEC on August
24, 2016. You should review a copy of the form of 2016 warrant for a complete description of the terms and conditions applicable
to the 2016 warrants. The offering and sale of the 2016 warrants, and the shares of common stock underlying the 2016 warrants,
were registered under the Prior Registration Statement.
Term. The 2016 warrants became exercisable six months after
the date of issuance for five years, but not thereafter.
Exercise Price. The exercise price of the 2016 warrants is
$2.60 per share. The exercise price and number of shares of our common stock issuable upon the exercise of the 2016 warrants is
subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization,
reorganization or similar transaction. The exercise price can also be lowered by us, with the prior written consent of
the holders of a majority in interest of the 2016 warrants then outstanding, unless prohibited by the listing rules of the
exchange on which our common stock is listed.
Exercisability. The 2016 warrants became exercisable commencing
six months after the date of issuance and are exercisable at any time during the applicable term of the 2016 warrant. The 2016 warrants
are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of shares of our common stock purchased upon such exercise. If there is no effective registration
statement registering the issuance of the shares underlying the 2016 warrants, then the 2016 warrants may be exercised by means of
a cashless exercise.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the 2016 warrants. As to any fraction of a share which the holder would otherwise
be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the exercise price of the 2016 warrant or round up to the next whole share.
Transferability. Subject to applicable laws, the 2016 warrants
may be transferred at the option of the holder upon surrender of the 2016 warrants to us together with the appropriate instruments
of transfer, provided that we may require an opinion of counsel in connection with certain transfers.
Authorized Shares. During the period the 2016 warrants are outstanding,
we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance of shares
of common stock underlying the 2016 warrants upon the exercise of the 2016 warrants.
Fundamental Transactions. In the event of any fundamental transaction,
as described in the 2016 warrants and generally including any merger with or into another entity, sale of all or substantially all
of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of a 2016
warrant the holder shall have the right to receive as alternative consideration, for each share of our common stock that would have
been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common
stock of the successor or acquiring corporation or of us, if we are the surviving corporation, and any additional consideration
receivable upon or as a result of such transaction by a holder of the number of shares of our common stock for which the 2016 warrant
is exercisable immediately prior to such event.
Right as a Stockholder. Except as otherwise provided in the
2016 warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the 2016 warrants do not
have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their 2016 warrants.
Waiver and Amendments. The terms of any 2016 warrant, other
than a lowering of the exercise price as described above, may be amended or waived with our written consent and the written consent
of the holder of such 2016 warrant.
Beneficial Ownership Limitation. Subject to limited exceptions,
a holder of 2016 warrants does not have the right to exercise any portion of its warrants if the holder, together with its affiliates,
would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect
to such exercise.
Financing Warrants
On March 24, 2017, we entered into an unsecured debt financing arrangement
with Stillwater Trust LLC, or Stillwater, an investor who with affiliates collectively control approximately 42% of our outstanding
common stock. In connection with the financing arrangement, Stillwater received a warrant to purchase 100,000 shares of our common
stock at an exercise price of $2.25 per share, the closing market price of our common stock on the date the financing arrangement was
executed. On May 24, 2017, we voluntarily terminated the financing arrangement. As of the date of its termination, there were no
amounts outstanding under the financing arrangement.
Term. The financing warrants became exercisable six months after
the date of issuance for five years, but not thereafter.
Exercise Price. The exercise price of the financing warrants
is $2.25 per share. The exercise price and number of shares of our common stock issuable upon the exercise of the financing warrants
is subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization
or similar transaction. The exercise price can also be lowered by us, with the prior written consent of the holders of a majority
in interest of the financing warrants then outstanding, unless prohibited by the listing rules of the exchange on which our common stock
is listed.
Exercisability. The financing warrants became exercisable commencing
six months after the date of issuance and are exercisable at any time during the applicable term of the financing warrant. The financing
warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice
accompanied by payment in full for the number of shares of our common stock purchased upon such exercise.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the financing warrants. As to any fraction of a share which the holder would
otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price of the financing warrant or round up to the next
whole share.
Transferability. Subject to applicable laws, the financing warrants
may be transferred at the option of the holder upon surrender of the financing warrants to us together with the appropriate instruments
of transfer, provided that we may require an opinion of counsel in connection with certain transfers.
Authorized Shares. During the period the financing warrants
are outstanding, we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance
of shares of common stock underlying the financing warrants upon the exercise of the financing warrants.
Fundamental Transactions. In the event of any fundamental transaction,
as described in the financing warrants and generally including any merger with or into another entity, sale of all or substantially
all of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of
a financing warrant the holder shall have the right to receive as alternative consideration, for each share of our common stock that
would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares
of common stock of the successor or acquiring corporation or of us, if we are the surviving corporation, and any additional consideration
receivable upon or as a result of such transaction by a holder of the number of shares of our common stock for which the financing warrant
is exercisable immediately prior to such event.
Right as a Stockholder. Except as otherwise provided in the
financing warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the financing warrants
do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their financing
warrants.
Waiver and Amendments. The terms of any financing warrant, other
than a lowering of the exercise price as described above, may be amended or waived with our written consent and the written consent
of the holder of such financing warrant.
2017 Warrants
The following description of our 2017 warrants is subject to, and
qualified in its entirety by, the form of 2017 warrant, which filed as an exhibit to our current report on Form 8-K filed with the
SEC on May 24, 2017. You should review a copy of the form of 2017 warrant for a complete description of the terms and conditions
applicable to the 2017 warrants. The offering and sale of the 2017 warrants, and the shares of common stock underlying the
2017 warrants, were registered under the Prior Registration Statement.
Term. The 2017 warrants are immediately exercisable upon issuance
for five years from the date of issuance, but not thereafter.
Exercise Price. The exercise price of the 2017 warrants is $2.45
per share. The exercise price and number of shares of our common stock issuable upon the exercise of the 2017 warrants is subject
to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization
or similar transaction. The exercise price can also be lowered by us, with the prior written consent of the holders of a majority
in interest of the 2017 warrants then outstanding, unless prohibited by the listing rules of the exchange on which our common stock
is listed.
Exercisability. The 2017 warrants are immediately exercisable
upon issuance and are exercisable at any time during the applicable term of the 2017 warrant. The 2017 warrants are exercisable,
at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in
full for the number of shares of our common stock purchased upon such exercise. If there is no effective registration statement registering
the issuance of the shares underlying the 2017 warrants, then the 2017 warrants may be exercised by means of a cashless
exercise.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the 2017 warrants. As to any fraction of a share which the holder would
otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price of the 2017 warrant or round up to the
next whole share.
Transferability. Subject to applicable laws, the 2017 warrants
may be transferred at the option of the holder upon surrender of the 2017 warrants to us together with the appropriate instruments
of transfer, provided that we may require an opinion of counsel in connection with certain transfers..
Authorized Shares. During the period the 2017 warrants
are outstanding, we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance
of shares of common stock underlying the 2017 warrants upon the exercise of the 2017 warrants.
Fundamental Transactions. In the event of any fundamental transaction,
as described in the 2017 warrants and generally including any merger with or into another entity, sale of all or substantially all
of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of a 2017
warrant the holder shall have the right to receive as alternative consideration, for each share of our common stock that would have
been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common
stock of the successor or acquiring corporation or of us, if we are the surviving corporation, and any additional consideration
receivable upon or as a result of such transaction by a holder of the number of shares of our common stock for which the 2017 warrant
is exercisable immediately prior to such event. Any successor to us or surviving entity is obligated to assume the obligations
under the Warrant.
Right as a Stockholder. Except as otherwise provided in the
2017 warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the 2017 warrants
do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their 2017
warrants.
Waiver and Amendments. The terms of any 2017 warrant,
other than a lowering of the exercise price as described above, may be amended or waived with our written consent and the written
consent of the holder of such 2017 warrant.
Beneficial Ownership Limitation. Subject to limited exceptions,
a holder of 2017 warrants does not have the right to exercise any portion of its warrants if the holder, together with its
affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after
giving effect to such exercise.
2018 Warrants
The following description of our 2018 warrants is subject to, and qualified
in its entirety by, the prospectus supplement filed on Form 424(b)(4) on January 25, 2018. You should review a copy of the prospectus
supplement for a complete description of the terms and conditions applicable to the 2018 warrants. The offering and sale
of the 2018 warrants, and the shares of common stock underlying the 2018 warrants, were registered under the Registration
Statement on Form S-1 (File No. 333-222375), as supplemented by the registration statement on Form S-1 filed pursuant to Rule 462(b) of
the Securities Act.
Term. The 2018 warrants are immediately exercisable upon issuance
for five years from the date of issuance, but not thereafter.
Exercise Price. The exercise price of the 2018 warrants subject
to the underwriting agreement is $1.35 per share. The exercise price and number of shares of our common stock issuable upon the exercise
of the 2018 warrants is subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend,
recapitalization, reorganization or similar transaction. The exercise price can also be lowered by us, with the prior written consent
of the holders of a majority in interest of the 2018 warrants then outstanding, unless prohibited by the listing rules of the exchange
on which our common stock is listed.
Exercisability. The 2018 warrants are immediately exercisable
upon issuance and are exercisable at any time during the applicable term of the 2018 warrant. The 2018 warrants are exercisable,
at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in
full for the number of shares of our common stock purchased upon such exercise. If there is no effective registration statement registering
the issuance of the shares underlying the 2018 warrants, then the 2018 warrants may be exercised by means of a cashless
exercise.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the 2018 warrants. As to any fraction of a share which the holder would
otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the exercise price of the 2018 warrant or round up to the next
whole share.
Transferability. Subject to applicable laws, the 2018 warrants
may be transferred at the option of the holder upon surrender of the 2018 warrants to us together with the appropriate instruments
of transfer, provided that we may require an opinion of counsel in connection with certain transfers.
Authorized Shares. During the period the 2018 warrants
are outstanding, we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance
of shares of common stock underlying the 2018 warrants upon the exercise of the 2018 warrants.
Fundamental Transactions. In the event of any fundamental transaction,
as described in the 2018 warrants and generally including any merger with or into another entity, sale of all or substantially all
of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of a 2018
warrant the holder shall have the right to receive as alternative consideration, for each share of our common stock that would have
been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common
stock of the successor or acquiring corporation or of us, if we are the surviving corporation, and any additional consideration
receivable upon or as a result of such transaction by a holder of the number of shares of our common stock for which the 2018 warrant
is exercisable immediately prior to such event. Any successor to us or surviving entity is obligated to assume the obligations
under the Warrant.
Right as a Stockholder. Except as otherwise provided in the
2018 warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the 2018 warrants
do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their 2018 warrants.
Waiver and Amendments. The terms of any 2018 warrant,
other than a lowering of the exercise price as described above, may be amended or waived with our written consent and the written
consent of the holder of such 2018 warrant.
Beneficial Ownership Limitation. Subject to limited exceptions,
a holder of 2018 warrants does not have the right to exercise any portion of its warrants if the holder, together with its
affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after
giving effect to such exercise.
In connection with the offering and sale of the 2018 warrants, certain
of our directors and executive officers, including our Chief Executive Officer and Chief Financial Officer, purchased $275,000 of shares
of our common stock and warrants in a separate concurrent private placement in a fixed combination at a public offering price of $1.35
and the same terms as described above. The sale of such shares of common stock and warrants in the concurrent private placement was not
registered under the Securities Act.
April 4, 2019 Warrants
The following description of our April 4, 2019 warrants is subject
to, and qualified in its entirety by, the form of April 4, 2019 warrant, which filed as exhibits to our current report on Form 8-K filed
with the SEC on April 8, 2019. You should review a copy of the form of April 4, 2019 warrant for a complete description of the terms
and conditions applicable to the April 4, 2019 warrants. You should review a copy of the form of April 4, 2019 warrant for a complete
description of the terms and conditions applicable to the April 4, 2019 warrants. The offering and sale of the April 4, 2019 warrants,
and the shares of common stock underlying the April 4, 2019 warrants, were not registered under the Securities Act, and were offered
pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.
Term. The April 4, 2019 warrants are exercisable six
months after issuance upon issuance for five and a half years from the date of issuance, but not thereafter.
Exercise Price. The exercise price of the April 4, 2019 warrants
is $0.78 per share. The exercise price and number of shares of our common stock issuable upon the exercise of the April 4, 2019 warrants
is subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization
or similar transaction. The exercise price can also be lowered by us, with the prior written consent of the holders of a majority
in interest of the April 4, 2019 warrants then outstanding, unless prohibited by the listing rules of the exchange on which our common stock
is listed.
Exercisability. The April 4, 2019 warrants are exercisable
six months after issuance and are exercisable at any time during the applicable term of the April 4, 2019 warrant. The April
4, 2019 warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. If there is no effective
registration statement registering the issuance of the shares underlying the April 4, 2019 warrants, then the April 4, 2019 warrants
may be exercised by means of a cashless exercise. In no circumstances will the Company be required to net settle the April 4, 2019
warrants.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the April 4, 2019 warrants. As to any fraction of a share which the holder
would otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of
such final fraction in an amount equal to such fraction multiplied by the exercise price of the April 4, 2019 warrant or round up to
the next whole share.
Transferability. Subject to applicable laws, the April 4, 2019 warrants
may be transferred at the option of the holder upon surrender of the April 4, 2019 warrants to us together with the appropriate instruments
of transfer, provided that we may require an opinion of counsel in connection with certain transfers.
Authorized Shares. During the period the April 4, 2019 warrants
are outstanding, we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance
of shares of common stock underlying the April 4, 2019 warrants upon the exercise of the April 4, 2019 warrants.
Fundamental Transactions. In the event of any fundamental
transaction, as described in the April 4, 2019 warrants and generally including any merger with or into another entity,
sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our common stock, then
upon any subsequent exercise of a April 4, 2019 warrant the holder shall have the right to receive as alternative
consideration, for each share of our common stock that would have been issuable upon such exercise immediately prior to the
occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation or
of us, if we are the surviving corporation, and any additional consideration receivable upon or as a result of such transaction
by a holder of the number of shares of our common stock for which the April 4, 2019 warrant is exercisable immediately prior to
such event. Any successor to us or surviving entity is obligated to assume the obligations under the Warrant.
Right as a Stockholder. Except as otherwise provided in the
April 4, 2019 warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the April
4, 2019 warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they
exercise their April 4, 2019 warrants.
Waiver and Amendments. The terms of any April 4, 2019 warrant,
other than a lowering of the exercise price as described above, may be amended or waived with our written consent and the written
consent of the holder of such April 4, 2019 warrant.
Beneficial Ownership Limitation. Subject to limited exceptions,
a holder of April 4, 2019 warrants does not have the right to exercise any portion of its warrants if the holder, together with
its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after
giving effect to such exercise.
April 9, 2019 Warrants
The following description of our April 9, 2019 warrants is subject
to, and qualified in its entirety by, the form of April 9, 2019 warrant, which filed as exhibits to our current reports on Form 8-K
filed with the SEC on April 11, 2019. You should review a copy of the form of April 9, 2019 warrant for a complete description
of the terms and conditions applicable to the April 9, 2019 warrants. The offering and sale of 4,000,000 additional shares of
the April 9, 2019 warrants at a negotiated purchase price of $0.49, and the shares of common stock underlying the April 9, 2019 warrants,
were registered under the Prior Registration Statement.
Term. The April 9, 2019 warrants are immediately exercisable
upon issuance for five years from the date of issuance, but not thereafter.
Exercise Price. The exercise price of the April 9, 2019 warrants
is $0.01 per share. The exercise price and number of shares of our common stock issuable upon the exercise of the April 9, 2019 warrants
is subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization
or similar transaction. The exercise price can also be lowered by us, with the prior written consent of the holders of a majority
in interest of the April 9, 2019 warrants then outstanding, unless prohibited by the listing rules of the exchange on which our common stock
is listed.
Exercisability. The April 9, 2019 warrants are immediately
exercisable upon issuance and are exercisable at any time during the applicable term of the 2019 warrant. The April 9, 2019 warrants
are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of shares of our common stock purchased upon such exercise. If there is no effective registration
statement registering the issuance of the shares underlying the April 9, 2019 warrants, then the April 9, 2019 warrants may
be exercised by means of a cashless exercise. In no circumstances will the Company be required to net settle the April 9, 2019
warrants.
No fractional shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of the April 9, 2019 warrants. As to any fraction of a share which the holder
would otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of
such final fraction in an amount equal to such fraction multiplied by the exercise price of the April 9, 2019 warrant or round up to
the next whole share.
Transferability. Subject to applicable laws, the April 9, 2019 warrants
may be transferred at the option of the holder upon surrender of the April 9, 2019 warrants to us together with the appropriate instruments
of transfer, provided that we may require an opinion of counsel in connection with certain transfers.
Authorized Shares. During the period the April 9, 2019 warrants
are outstanding, we will reserve from our authorized and unissued common stock a sufficient number of shares to provide for the issuance
of shares of common stock underlying the April 9, 2019 warrants upon the exercise of the April 9, 2019 warrants.
Fundamental Transactions. In the event of any fundamental transaction,
as described in the April 9, 2019 warrants and generally including any merger with or into another entity, sale of all or substantially
all of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of
a April 9, 2019 warrant the holder shall have the right to receive as alternative consideration, for each share of our common
stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number
of shares of common stock of the successor or acquiring corporation or of us, if we are the surviving corporation, and any additional
consideration receivable upon or as a result of such transaction by a holder of the number of shares of our common stock
for which the April 9, 2019 warrant is exercisable immediately prior to such event. Any successor to us or surviving entity
is obligated to assume the obligations under the Warrant.
Right as a Stockholder. Except as otherwise provided in the
April 9, 2019 warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the April
9, 2019 warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they
exercise their April 9, 2019 warrants.
Waiver and Amendments. The terms of any April 9, 2019 warrant,
other than a lowering of the exercise price as described above, may be amended or waived with our written consent and the written
consent of the holder of such April 9, 2019 warrant.
Beneficial Ownership Limitation. Subject to limited exceptions,
a holder of April 9, 2019 warrants does not have the right to exercise any portion of its warrants if the holder, together with
its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after
giving effect to such exercise.
In connection with the offering and sale of the April 9, 2019 warrants,
certain of the purchasers of the April 9, 2019 warrants purchased 3,000,000 warrants issuable upon exercise of the April 9, 2019 warrants
and exercisable six months after issuance at an initial exercise price of $0.78 and expiring five and a half years after the date of issuance.
Such warrants are otherwise subject to the same terms as the April 9, 2019 warrants described above. The sale of such shares of common
stock and warrants in the concurrent private placement was not registered under the Securities Act.
Preferred Stock
We may issue shares of our preferred stock from time to time, in one
or more series. The 10,000,000 shares of preferred stock authorized are undesignated as to preferences, privileges and restrictions. Our
Board of Directors will determine the rights, preferences and privileges of the shares of each wholly unissued series, and any qualifications,
limitations or restrictions thereon, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase,
liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series.
On December 19, 2008, we filed a Certificate of
Designations with the State of Delaware which designates 10,000 shares of our preferred stock as Series B Convertible Preferred
Stock. The preferred stock has a stated value of $1,000 and has a conversion price of $0.75 per share. The preferred stock does
not pay interest. The holders of the preferred stock are not entitled to receive dividends unless the Board of
Directors declares a dividend for holders of our common stock and then the dividend shall be equal to the amount that such
holder would have been entitled to receive if the holder converted its preferred stock into shares of our common stock. Each
share of preferred stock has voting rights equal to (i) the number of shares of our common stock issuable upon conversion of
such shares of preferred stock at such time (determined without regard to the shares of common stock so issuable upon such
conversion in respect of accrued and unpaid dividends on such share of preferred stock) when the preferred stock votes together
with our common stock or any other class or series of our capital stock and (ii) one vote per share of preferred stock when
such vote is not covered by the immediately preceding clause. In the event of our liquidation, dissolution, or winding up, the
preferred stock is entitled to receive liquidation preference before the common stock. We may at our option redeem the
preferred stock by providing the required notice to the holders of the preferred stock and paying an amount equal to $1,000
multiplied by the number of shares for all of such holder’s shares of outstanding preferred stock to be redeemed.
If we sell any series of preferred stock under this prospectus, we
will fix the rights, preferences and privileges of the preferred stock of such series, as well as any qualifications, limitations or restrictions
thereon, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation
that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. We urge
you to read the applicable prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to
the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable
series of preferred stock.
The General Corporation Law of the State of Delaware, the state of
our incorporation, provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases,
as a series) on an amendment to our amended and restated certificate of incorporation if the amendment would change the par value, the
number of authorized shares of the class or the powers, preferences or special rights of the class or series so as to adversely affect
the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate
of designation.
Our Board of Directors may authorize the issuance of preferred stock
with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The
issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could,
among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price
of the common stock and the voting and other rights of the holders of common stock. Additionally, the issuance of preferred stock may
have the effect of decreasing the market price of our common stock.
Delaware Law and Certain Charter and By-law Provisions
Provisions of Delaware law, our certificate of incorporation and our
by-laws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable. These
provisions may also prevent or delay attempts by stockholders to replace or remove our current management or members of our Board
of Directors. These provisions include:
|
●
|
limitations
on the removal of directors;
|
|
●
|
advance
notice requirements for stockholder proposals and nominations;
|
|
●
|
the inability of stockholders to act by written consent or
to call special meetings;
|
|
●
|
the ability of our Board of Directors to make, alter or repeal
our by-laws; and
|
|
●
|
the
authority of our Board of Directors to issue preferred stock with such terms as our Board of Directors may determine.
|
In addition, we are subject to the provisions of Section 203 of the
Delaware General Corporation Law statute. Section 203 prohibits a publicly-held Delaware corporation from engaging in a “business
combination” with an “interested stockholder” for a period of three years after the person became an interested
stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes mergers,
asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder”
is a person who, together with affiliates and associates, owns, or within the prior three years did own, 15% or more of the corporation’s
voting stock.
Our certificate of incorporation contains certain provisions permitted
under Delaware General Corporation Law relating to the liability of directors. The provisions eliminate a director’s liability
for monetary damages for a breach of fiduciary duty, except in certain circumstances where such liability may not be eliminated under
applicable law. Further, our certificate of incorporation contains provisions to indemnify our directors and officers to the fullest
extent permitted by Delaware General Corporation Law.
Transfer Agent and Registrar
Our transfer agent and registrar for our common stock is Continental
Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, NY 10004.
Listing
Our common stock is listed on NYSE American, under the symbol
“EMAN.”
DESCRIPTION OF OUR DEBT SECURITIES
The following description, together with the additional information
we include in any applicable prospectus supplements or free writing prospectuses that we may authorize to be distributed to purchasers,
summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. We refer to the senior and
subordinated debt and senior and subordinated convertible debt collectively as debt securities. While the terms we have summarized below
will generally apply to any future debt securities we may offer under this prospectus, a prospectus supplement or free writing prospectus
will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement or
free writing prospectus. The terms of any debt securities we offer under a prospectus supplement or free writing prospectus may differ
from the general terms we describe below.
We may issue senior debt securities from time to time, in one or more
series, under a senior indenture to be entered into between us and a senior trustee to be named in a prospectus supplement, which we refer
to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series, under a subordinated indenture
to be entered into between us and a subordinated trustee to be named in a prospectus supplement, which we refer to as the subordinated
trustee. The forms of senior indenture and subordinated indenture are filed as exhibits to this registration statement of which this prospectus
forms a part. Together, the senior indenture and the subordinated indenture are referred to as the indentures and, together, the senior
trustee and the subordinated trustee are referred to as the trustees. This prospectus briefly outlines some of the provisions of the indentures.
None of the indentures will limit the amount of debt securities that
we may issue. The applicable indenture will provide that debt securities may be issued up to an aggregate principal amount authorized
from time to time by us and may be payable in any currency or currency unit designated by us or in amounts determined by reference to
an index.
The following summaries of material provisions of the senior debt securities,
the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions
of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement or free
writing prospectus and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as
well as the complete applicable indenture that contains the terms of the debt securities.
General
We will describe in the applicable prospectus supplement or free writing
prospectus the terms of the series of debt securities being offered, including:
|
●
|
the
principal amount being offered, and if a series, the total amount authorized and the total amount outstanding;
|
|
●
|
any
limit on the amount that may be issued;
|
|
●
|
whether
or not we will issue the series of debt securities in global form, and, if so, the terms and who the depository will be;
|
|
●
|
whether
and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States
person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;
|
|
●
|
the
annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue,
the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;
|
|
●
|
whether
or not the debt securities will be secured or unsecured, and the terms of any secured debt;
|
|
●
|
the
terms of the subordination of any series of subordinated debt;
|
|
●
|
the
place where payments will be payable;
|
|
●
|
restrictions
on transfer, sale or other assignment, if any;
|
|
●
|
our
right, if any, to defer payment of interest and the maximum length of any such deferral period;
|
|
●
|
the
date, if any, after which, the conditions upon which, and the price at which, we may, at our option, redeem the series of debt securities
pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;
|
|
●
|
the
date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions
or otherwise, to redeem, or at the holder’s option, to purchase, the series of debt securities and the currency or currency unit
in which the debt securities are payable;
|
|
●
|
whether
the indenture will restrict our ability or the ability of our subsidiaries to:
|
|
●
|
incur
additional indebtedness;
|
|
●
|
issue
additional securities;
|
|
●
|
pay
dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries;
|
|
●
|
place
restrictions on our subsidiaries’ ability to pay dividends, make distributions or transfer assets;
|
|
●
|
make
investments or other restricted payments;
|
|
●
|
sell
or otherwise dispose of assets;
|
|
●
|
enter
into sale-leaseback transactions;
|
|
●
|
engage
in transactions with stockholders or affiliates;
|
|
●
|
issue
or sell stock of our subsidiaries; or
|
|
●
|
effect
a consolidation or merger;
|
|
●
|
whether
the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;
|
|
●
|
a
discussion of certain material or special United States federal income tax considerations applicable to the debt securities;
|
|
●
|
information
describing any book-entry features;
|
|
●
|
provisions
for a sinking fund purchase or other analogous fund, if any;
|
|
●
|
the
applicability of the provisions in the indenture on discharge;
|
|
●
|
whether
the debt securities are to be offered at a price such that they will be deemed to be offered at an “original issue discount”
as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended;
|
|
●
|
the
denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;
|
|
●
|
the
currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;
and
|
|
●
|
any other specific terms, preferences, rights or limitations
of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt
securities, and any terms that may be required by us or advisable under applicable laws or regulations or advisable in connection with
the marketing of the debt securities.
|
We may, from time to time, without notice to or the consent of the
holders of any series of debt securities, create and issue further debt securities of any such series ranking equally with the debt securities
of such series in all respects (or in all respects other than (a) the payment of interest accruing prior to the issue date of such
further debt securities or (b) the first payment of interest following the issue date of such further debt securities). Such further
debt securities may be consolidated and form a single series with the debt securities of such series and have the same terms as to status,
redemption or otherwise as the debt securities of such series.
Certain Terms of the Senior Debt Securities
Conversion or Exchange Rights. We will set forth in the
applicable prospectus supplement or free writing prospectus the terms on which a series of senior debt securities may be convertible into
or exchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include
provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions
pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party)
that the holders of the series of senior debt securities receive would be subject to adjustment.
Consolidation, Merger or Sale. Unless we provide otherwise
in the prospectus supplement or free writing prospectus applicable to a particular series of senior debt securities, the senior debt securities
will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all
or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the
senior indenture or the senior debt securities, as appropriate. If the senior debt securities are convertible into or exchangeable for
other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property
must make provisions for the conversion of the senior debt securities into securities that the holders of the senior debt securities would
have received if they had converted the senior debt securities before the consolidation, merger or sale.
No Protection in the Event of a Change in Control. Unless we
indicate otherwise in a prospectus supplement or free writing prospectus applicable to a particular series of senior debt securities,
the senior debt securities will not contain any provisions that may afford holders of the senior debt securities protection in the event
we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in
control).
Events of Default. Unless we provide otherwise in the prospectus
supplement or free writing prospectus applicable to a particular series of senior debt securities, the following are events of default
under the senior indenture with respect to any series of senior debt securities that we may issue:
|
●
|
if
we fail to pay interest when due and payable and our failure continues for 90 days (or such other period as may be specified for
such series) and the time for payment has not been extended;
|
|
●
|
if
we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase
or otherwise (and, if specified for such series, the continuance of such failure for a specified period), and the time for payment has
not been extended;
|
|
●
|
if
we fail to observe or perform any other covenant contained in the senior debt securities or the senior indenture, other than a covenant
that is specifically dealt with elsewhere in the senior indenture, and our failure continues for 90 days after we receive notice
from the senior trustee or holders of at least 25% in aggregate principal amount of the outstanding senior debt securities of the applicable
series; and
|
|
●
|
if
specified events of bankruptcy, insolvency or reorganization occur.
|
We will describe in each applicable prospectus supplement or free writing
prospectus any additional events of default relating to the relevant series of senior debt securities.
If an event of default with respect to senior debt securities of any
series occurs and is continuing, other than an event of default specified in the last bullet point above, the senior trustee or the holders
of at least 25% in aggregate principal amount of the outstanding senior debt securities of that series, by notice to us in writing, and
to the senior trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if
any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the unpaid
principal, premium, if any, and accrued interest, if any, of each issue of senior debt securities then outstanding shall be due and payable
without any notice or other action on the part of the senior trustee or any holder.
Unless otherwise specified in the prospectus supplement or free writing
prospectus applicable to a particular series of senior debt securities originally issued at a discount, the amount due upon acceleration
shall include only the original issue price of the senior debt securities, the amount of original issue discount accrued to the date of
acceleration and accrued interest, if any.
The holders of a majority in principal amount of the outstanding senior
debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except
defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event
of default in accordance with the senior indenture. Any waiver shall cure the default or event of default.
Upon certain conditions, declarations of acceleration may be rescinded
and annulled and past defaults may be waived by the holders of a majority in aggregate principal amount of all the senior debt securities
of such series affected by the default. Furthermore, prior to a declaration of acceleration and subject to various provisions in the senior
indenture, the holders of a majority in aggregate principal amount of a series of senior debt securities, by notice to the senior trustee,
may waive an existing default or event of default with respect to such senior debt securities and its consequences, except a default in
the payment of principal of, premium, if any, on or interest on such senior debt securities. Upon any such waiver, such default shall
cease to exist, and any event of default with respect to such senior debt securities shall be deemed to have been cured, for every purpose
of the senior indenture, but no such waiver shall extend to any subsequent or other default or event of default or impair any right consequent
thereto.
The holders of a majority in aggregate principal amount of a series
of senior debt securities will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the senior trustee or exercising any trust or power conferred on the senior trustee with respect to such senior debt securities. However,
the senior trustee may refuse to follow any direction that conflicts with law or the senior indenture that may involve the senior trustee
in personal liability or that the senior trustee determines in good faith may be unduly prejudicial to the rights of holders of such series
of senior debt securities not joining in the giving of such direction and may take any other action it deems proper that is not inconsistent
with any such direction received from holders of such series of senior debt securities. A holder of the senior debt securities of any
series will have the right to institute a proceeding under the senior indenture or to appoint a receiver or senior trustee, or to seek
other remedies if:
|
●
|
the
holder has given written notice to the senior trustee of a continuing event of default with respect to that series;
|
|
●
|
the
holders of at least 25% in aggregate principal amount of the outstanding senior debt securities of that series have made written request,
and such holders have offered reasonable indemnity to the senior trustee or security satisfactory to it against any loss, liability or
expense or to be incurred in compliance with instituting the proceeding as trustee; and
|
|
●
|
the
senior trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of
the outstanding senior debt securities of that series other conflicting directions within 90 days after the notice, request and
offer.
|
These limitations do not apply to a suit instituted by a holder of
senior debt securities if we default in the payment of the principal, premium, if any, or interest on, the senior debt securities, or
other defaults that may be specified in the applicable prospectus supplement or free writing prospectus.
Modification and Waiver. We and the senior trustee may amend,
supplement or modify the senior indenture or the senior debt securities without the consent of any holders with respect to the following
specific matters:
|
●
|
to
fix any ambiguity, defect or inconsistency in the senior indenture or to conform the senior indenture or the senior debt securities to
the description of senior debt securities of such series set forth in this prospectus or any applicable prospectus supplement or any
free writing supplement;
|
|
●
|
to
convey, transfer, assign, mortgage or pledge any assets as security for the senior debt securities of one or more series;
|
|
●
|
to
add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication
and delivery of senior debt securities;
|
|
●
|
to
evidence the succession of another corporation, and the assumption by such successor corporation of our covenants, agreements and obligations
under the senior indenture;
|
|
●
|
to
provide for or add guarantors with respect to the senior debt securities of any series;
|
|
●
|
to
establish the form of any certifications required to be furnished pursuant to the terms of the senior indenture or any series of senior
debt securities, or to add to the rights of the holders of any series of senior debt securities;
|
|
●
|
to
evidence and provide for the acceptance of appointment hereunder by a successor senior trustee or to make such changes as shall be necessary
to provide for or facilitate the administration of the trusts in the senior indenture by more than one trustee;
|
|
●
|
to
make any change to the senior debt securities of any series, so long as no senior debt securities of such series are outstanding
|
|
●
|
to
provide for uncertificated senior debt securities and to make all appropriate changes for such purpose;
|
|
●
|
to
add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence,
or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event
of default or to surrender any right or power conferred to us in the senior indenture; or
|
|
●
|
to
change anything that does not materially adversely affect the interests of any holder of senior debt securities of any series.
|
Other amendments and modifications of the senior indenture or the senior
debt securities issued may be made, and our compliance with any provision of the senior indenture with respect to any series of senior
debt securities may be waived, with the consent of the holders of a majority of the aggregate principal amount of the outstanding senior
debt securities of all series affected by the amendment or modification (voting together as a single class); provided, however, that each
affected holder must consent to any modification, amendment or waiver that:
|
●
|
extends
the stated maturity of any senior debt securities;
|
|
●
|
reduces
the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption
or repurchase of any senior debt securities;
|
|
●
|
reduces
the rate or extends the time of payment of interest on any senior debt securities; or
|
|
●
|
reduces
the percentage of senior debt securities, the holders of which are required to consent to any amendment, supplement, modification or
waiver.
|
Satisfaction and Discharge. We can elect satisfy and discharge
our obligations with respect to one or more series of senior debt securities, except for specified obligations, including obligations
to:
|
●
|
register
the transfer or exchange of debt securities of the series;
|
|
●
|
replace
stolen, lost or mutilated debt securities of the series;
|
|
●
|
maintain
paying agencies;
|
|
●
|
hold
monies for payment in trust;
|
|
●
|
recover
excess money held by the senior trustee;
|
|
●
|
compensate
and indemnify the senior trustee; and
|
|
●
|
appoint
any successor senior trustee.
|
In order to exercise our rights to be discharged, we must deposit with
the senior trustee money or government obligations sufficient to pay all the principal of, any premium and interest on, the senior debt
securities of the series on the dates payments are due.
Under current U.S. federal income tax law, the deposit and our legal
release from the senior debt securities would be treated as though we took back a holder’s senior debt securities and gave such
holder his or her share of the cash and debt securities or bonds deposited in trust. In that event, such holder could recognize gain or
loss on the senior debt securities such holder gives back to us. Holders of the senior debt securities should consult their own advisers
with respect to the tax consequences to them of such deposit and discharge, including the applicability and effect of tax laws other than
the U.S. federal income tax law.
Information Concerning the Senior Trustee. The senior trustee,
other than during the occurrence and continuance of an event of default under the senior indenture, undertakes to perform only those duties
as are specifically set forth in the applicable senior indenture and no implied covenants or obligations shall be read into the senior
indenture against the senior trustee. Upon the occurrence and during the continuation of an event of default under the senior
indenture, the senior trustee must use the same degree of care as a prudent person would exercise or use under the circumstances in the
conduct of his or her own affairs.
Subject to this provision, the senior trustee is under no obligation
to exercise any of the powers given it by the senior indenture at the request of any holder of senior debt securities unless it is offered
reasonable security and indemnity against the costs, expenses and liabilities that it might incur.
We may have normal banking relationships with the senior trustee in
the ordinary course of business.
Certain Terms of the Subordinated Debt Securities
Other than the terms of the subordinated indenture and subordinated
debt securities relating to subordination or otherwise as described in the prospectus supplement or free writing prospectus relating to
a particular series of subordinated debt securities, the terms of the subordinated indenture and subordinated debt securities are identical
in all material respects to the terms of the senior indenture and senior debt securities.
Additional or different subordination terms may be specified in the
prospectus supplement applicable to a particular series.
Subordination. The indebtedness evidenced by the
subordinated debt securities is subordinate to the prior payment in full of all of our senior indebtedness, as defined in the
subordinated indenture. During the continuance beyond any applicable grace period of any default in the payment of principal,
premium, interest or any other payment due on any of our senior indebtedness, we may not make any payment of principal of, or
premium, if any, on or interest on the subordinated debt securities (except for certain sinking fund payments). In addition, upon
any payment or distribution of our assets upon any dissolution, winding-up, liquidation or reorganization, the payment of the
principal of, or premium, if any, on and interest on the subordinated debt securities will be subordinated to the extent provided in
the subordinated indenture in right of payment to the prior payment in full of all our senior indebtedness. Because of this
subordination, if we dissolve or otherwise liquidate, holders of our subordinated debt securities may receive less, ratably, than
holders of our senior indebtedness. The subordination provisions do not prevent the occurrence of an event of default under the
subordinated indenture.
Governing Law
The indentures and the debt securities will be governed by and construed
in accordance with the internal laws of the State of New York.
Ranking of Debt Securities
The senior debt securities will rank equally in right of payment to
all our other senior unsecured debt. The subordinated debt securities will be subordinate and junior in priority of payment to certain
of our other indebtedness (including senior debt securities) to the extent described in a prospectus supplement or free writing prospectus.
DESCRIPTION OF WARRANTS
The following description, together with the additional information
we include in any applicable prospectus supplements or free writing prospectuses that we may authorize to be distributed to purchasers,
summarizes the material terms and provisions of the warrants that we may offer under this prospectus. Warrants may be offered independently
or together with common stock, preferred stock and/or debt securities offered by any prospectus supplement or free writing prospectus,
and may be attached to or separate from those securities. While the terms we have summarized below will generally apply to any future
warrants we may offer under this prospectus, we will describe the particular terms of any warrants that we may offer in more detail in
the applicable prospectus supplement or free writing prospectus. The terms of any warrants we offer under a prospectus supplement or free
writing prospectus may differ from the general terms we describe below. If there are differences between that prospectus supplement and
this prospectus, the prospectus supplement will control. Thus, the statements we make in this section may not apply to
a particular series of warrants.
We will file as exhibits to the registration statement of which this
prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, including
a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the
related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to,
and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the
particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related
to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the
complete warrant agreements and warrant certificates that contain the terms of the warrants.
General
We will describe in the applicable prospectus supplement the terms
of the series of warrants being offered. If warrants for the purchase of debt securities are offered, the prospectus supplement or free
writing prospectus will describe the following terms, to the extent applicable:
|
●
|
the
offering price and the aggregate number of warrants offered;
|
|
●
|
the
currencies in which the warrants are being offered;
|
|
●
|
the
designation, aggregate principal amount, currencies, denominations and terms of the series of debt securities that can be purchased if
a holder exercises a warrant;
|
|
●
|
the
designation and terms of any series of debt securities with which the warrants are being offered and the number of warrants offered with
each such debt security;
|
|
●
|
the
date on and after which the holder of the warrants can transfer them separately from the related series of debt securities;
|
|
●
|
the
principal amount of the series of debt securities that can be purchased if a holder exercises a warrant and the price at which and currencies
in which such principal amount may be purchased upon exercise;
|
|
●
|
the
terms of any rights to redeem or call the warrants;
|
|
●
|
the
date on which the right to exercise the warrants begins and the date on which such right expires;
|
|
●
|
federal
income tax consequences of holding or exercising the warrants; and
|
|
●
|
any
other specific terms, preferences, rights or limitations of, or restrictions on, the warrants.
|
Warrants for the purchase of debt securities will be in registered
form only.
If warrants for the purchase of common stock or preferred stock are
offered, the prospectus supplement or free writing prospectus will describe the following terms, to the extent applicable:
|
●
|
the
offering price and aggregate number of warrants offered;
|
|
●
|
the
currency for which the warrants may be purchased;
|
|
●
|
if
applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each
such security or each principal amount of such security;
|
|
●
|
if
applicable, the date on and after which the warrants and the related securities will be separately transferable;
|
|
●
|
the
number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at
which these shares may be purchased upon such exercise;
|
|
●
|
the
warrant agreement, if any, under which the warrants will be issued;
|
|
●
|
the
effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;
|
|
●
|
anti-dilution
provisions of the warrants if any;
|
|
●
|
the
terms of any rights to redeem or call the warrants;
|
|
●
|
any
provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;
|
|
●
|
the
dates on which the right to exercise the warrants will commence and expire;
|
|
●
|
the
manner in which the warrant agreements and warrants may be modified;
|
|
●
|
the
identities and addresses of the warrant agent and any calculation or other agent for the warrants;
|
|
●
|
the
terms of the securities issuable upon exercise of the warrants;
|
|
●
|
any
securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants may be listed;
and
|
|
●
|
any
other specific terms, preferences, rights or limitations of or restrictions on the warrants.
|
Before exercising their warrants, holders of warrants will not have
any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends, if any, or, payments
upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
Exercise of Warrants
Each warrant will entitle the holder to purchase the securities that
we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless
we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the
specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration
date, unexercised warrants will become void.
Holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the
warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side
of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required
to deliver to the warrant agent.
Until the warrant is properly exercised, no holder of any warrant will
be entitled to any rights of a holder of the securities purchasable upon exercise of the warrant.
Upon receipt of the required payment and the warrant certificate properly
completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus
supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by
the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate
in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.
Governing Law
Unless we provide otherwise in the applicable prospectus supplement,
the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of New York.
Enforceability of Rights by Holders of Warrants
Any warrant agent will act solely as our agent under the applicable
warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank
or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in
case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings
at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the
holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise
of, its warrants in accordance with the terms of such warrants.
Calculation Agent
Calculations relating to warrants may be made by a calculation agent,
an institution that we appoint as our agent for this purpose. The prospectus supplement for a particular warrant will name the institution
that we have appointed to act as the calculation agent for that warrant as of the original issue date for that warrant. We may appoint
a different institution to serve as calculation agent from time to time after the original issue date without the consent or notification
of the holders.
The calculation agent’s determination of any amount of money
payable or securities deliverable with respect to a warrant will be final and binding in the absence of manifest error.
DESCRIPTION OF UNITS
The following description, together with the additional information
that we include in any applicable prospectus supplements or free writing prospectuses that we may authorize to be distributed to purchasers,
summarizes the material terms and provisions of the units that we may offer under this prospectus. We may issue, in one more series, units
consisting of common stock, preferred stock, debt securities and/or warrants for the purchase of common stock and/or preferred stock in
any combination. While the terms we have summarized below will generally apply to any future series of units we may offer under this prospectus,
we will describe the particular terms of any series of units that we may offer in more detail in the applicable prospectus supplement
or free writing prospectus. The terms of any series of units we offer under a prospectus supplement or free writing prospectus may differ
from the general of terms we described below.
We will file as exhibits to the registration statement of which this
prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement that describes
the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units.
The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to,
all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read
the applicable prospectus supplements related to the particular series of units that we may offer under this prospectus, as well as any
related free writing prospectuses and the complete unit agreement and any supplemental agreements that contain the terms of the units.
General
Each unit will be issued so that the holder of the unit is also the
holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included
security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred
separately, at any time or at any time before a specified date.
We will describe in the applicable prospectus supplement the terms
of the series of units being offered, including:
|
●
|
the
designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities
may be held or transferred separately;
|
|
●
|
any
provisions of the governing unit agreement that differ from those described below in this section;
|
|
●
|
any
provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and
|
|
●
|
whether
the units will be issued in fully registered or global form.
|
The provisions described in this section, as well as those described
under “Description of Capital Stock” and “Description of Warrants” will apply to each unit and to any common stock,
preferred stock or warrant included in each unit, respectively.
Issuance in Series
We may issue units in such amounts and in such numerous distinct series
as we determine.
Enforceability of Rights by Holders of Units
Each unit agent will act solely as our agent under the applicable unit
agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company
may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us
under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or
to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce
by appropriate legal action its rights as holder under any security included in the unit.
Title
We, and any unit agent and any of their agents, may treat the registered
holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled
to exercise the rights attaching to the units so requested, despite any notice to the contrary.
FORMS OF SECURITIES
General
Each debt security, unit and warrant will be represented either by
a certificate issued in definitive form to a particular purchaser or by one or more global securities representing the entire issuance
of securities. Unless the applicable prospectus supplement provides otherwise, certificated securities in definitive form and global securities
will be issued in registered form. Definitive securities name you or your nominee as the owner of the security, and in order to transfer
or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically
deliver the securities to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its
nominee as the owner of the debt securities, units or warrants represented by these global securities. The depositary maintains a computerized
system that will reflect each purchaser’s beneficial ownership of the securities through an account maintained by the purchaser
with its broker/dealer, bank, trust company or other representative, as we explain more fully below.
Registered Global Securities
We may issue the registered debt securities, units and warrants in
the form of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the applicable
prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global securities
will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities
to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive registered form,
a registered global security may not be transferred except as a whole by and among the depositary for the registered global security,
the nominees of the depositary or any successors of the depositary or those nominees.
If not described below, any specific terms of the depositary arrangement
with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating
to those securities. We anticipate that the following provisions will apply to all depositary arrangements.
Ownership of beneficial interests in a registered global security will
be limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants.
Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the
participants’ accounts with the respective principal or face amounts of the securities beneficially owned by the participants. Any
dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership
of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only
through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect
to interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical
delivery of these securities in definitive form. These laws may impair such purchasers’ abilities to own, transfer or pledge beneficial
interests in registered global securities.
So long as the depositary, or its nominee, is the registered
owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or
holder of the securities represented by the registered global security for all purposes under the applicable indenture, unit
agreement or warrant agreement. Except as described below, owners of beneficial interests in a registered global security will not
be entitled to have the securities represented by the registered global security registered in their names, will not receive or be
entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders of the
securities under the applicable indenture, unit agreement or warrant agreement. Accordingly, each person owning a beneficial
interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if
that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any
rights of a holder under the applicable indenture, unit agreement or warrant agreement. We understand that under existing industry
practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to
give or take any action that a holder is entitled to give or take under the applicable indenture, unit agreement or warrant
agreement, the depositary for the registered global security would authorize the participants holding the relevant beneficial
interests to give or take that action, and the participants would authorize beneficial owners owning through them to give or take
that action or would otherwise act upon the instructions of beneficial owners holding through them.
Principal, premium, if any, on and interest payments on debt securities,
and any payments to holders with respect to warrants, or units, represented by a registered global security registered in the name of
a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the registered
global security. None of us, the trustees, the warrant agents, the unit agents or any other agent of ours, agent of the trustees or agent
of the warrant agents or unit agents will have any responsibility or liability for any aspect of the records relating to payments made
on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records
relating to those beneficial ownership interests.
We expect that the depositary for any of the securities represented
by a registered global security, upon receipt of any payment of principal, premium, interest or other distribution of underlying securities
or other property to holders on that registered global security, will immediately credit participants’ accounts in amounts proportionate
to their respective beneficial interests in that registered global security as shown on the records of the depositary. We also expect
that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed
by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers or
registered in “street name,” and will be the responsibility of those participants.
If the depositary for any of the securities represented by a registered
global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Securities
Exchange Act of 1934, as amended, or Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is
not appointed by us within 90 days, we will issue securities in definitive form in exchange for the registered global security that had
been held by the depositary. Any securities issued in definitive form in exchange for a registered global security will be registered
in the name or names that the depositary gives to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs.
It is expected that the depositary’s instructions will be based upon directions received by the depositary from participants with
respect to ownership of beneficial interests in the registered global security that had been held by the depositary.
LEGAL MATTERS
The validity of the securities being offered by this prospectus will
be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. If the validity of any securities is also passed upon by counsel
any underwriters, dealers or agents, that counsel will be named in the prospectus supplement relating to that specific offering.
EXPERTS
The consolidated financial statements of eMagin Corporation as of December
31, 2019 and 2018 and for each of the years in the two-year period ended December 31, 2019 incorporated in this Prospectus by reference
from the eMagin Corporation Annual Report on Form 10-K for the year ended December 31, 2019 have been audited by RSM US LLP, an independent
registered public accounting firm, as stated in their report thereon (which report expresses an unqualified opinion and includes an explanatory
paragraph related to an emphasis of matter regarding going concern), incorporated herein by reference, and have been incorporated in this
Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.
$10,000,000
eMagin
Corporation
Common
Stock
PROSPECTUS
SUPPLEMENT
H.C.
Wainwright & Co.
November
18, 2021
eMagin (AMEX:EMAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
eMagin (AMEX:EMAN)
Historical Stock Chart
From Jul 2023 to Jul 2024